0001213900-23-045798.txt : 20230602 0001213900-23-045798.hdr.sgml : 20230602 20230602163036 ACCESSION NUMBER: 0001213900-23-045798 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Genufood Energy Enzymes Corp. CENTRAL INDEX KEY: 0001510518 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 680681158 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56112 FILM NUMBER: 23989309 BUSINESS ADDRESS: STREET 1: 1108 S. BALWAIN AVENUE, SUITE 107 CITY: ARCADIA STATE: CA ZIP: 91007 BUSINESS PHONE: (855) 707-2077 MAIL ADDRESS: STREET 1: 1108 S. BALWAIN AVENUE, SUITE 107 CITY: ARCADIA STATE: CA ZIP: 91007 10-Q 1 f10q0323_genufood.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023

 

Commission File Number 000-56112

 

GENUFOOD ENERGY ENZYMES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

(State or other jurisdiction of incorporation or organization)

 

1108 S. Baldwin Avenue, Suite 107

Arcadia, California 91007

(Address of principal executive offices, including zip code.)

 

(855) 707-2077

(Telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
N/A    N/A    N/A 

 

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES ☒  NO 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES    NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES    NO

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 808,900,041 shares as of March 31, 2023. 

 

 

 

 

 

GENUFOOD ENERGY ENZYMES CORP.

 

FORM 10-Q FOR THE SIX-MONTH PERIOD ENDED MARCH 31, 2023

 

TABLE OF CONTENTS

 

    Page
Number
  PART I. FINANCIAL INFORMATION  
     
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 13
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 18
ITEM 4. CONTROLS AND PROCEDURES 18
     
  PART II. OTHER INFORMATION 20
     
ITEM 1. LEGAL PROCEEDINGS 20
ITEM 1A. RISK FACTORS 20
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 20
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 20
ITEM 4. MINE SAFETY DISCLOSURES 20
ITEM 5. OTHER INFORMATION 20
ITEM 6. EXHIBITS 21

 

i

 

 

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   March 31,   September 30, 
   2023   2022 
   (Unaudited)   (Restated) 
ASSETS        
CURRENT ASSETS        
Cash and cash equivalents  $311,133   $136,400 
Prepayment   9,537    14,493 
Total Current Assets   320,670    150,893 
Equipment   20,167    
-
 
Total Assets  $340,837   $150,893 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $100,115   $102,185 
Accrued expenses   40    
-
 
Due to related parties   4,776    102,831 
Total Current Liabilities   104,931    205,016 
           
Commitment and contingencies (Note 9)   30,726    29,226 
           
STOCKHOLDERS’ EQUITY (DEFICIT)          
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively   808,900    299,687 
Additional paid-in capital   16,952,092    16,927,592 
Discount on common stock   (7,241,581)   (7,241,581)
Accumulated deficit   (10,314,231)   (9,875,489)
Accumulated other comprehensive loss   
-
    (193,558)
Total Stockholders’ Equity (Deficit)   205,180    (83,349)
           
Total Liabilities and Stockholders’ Equity  $340,837   $150,893 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

1

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

 

   For the Three Months Ended March 31,   For the Six Months Ended March 31, 
   2023   2022   2023   2022 
REVENUE  $
-
   $
-
   $
-
   $
-
 
                     
OPERATING EXPENSES                    
General and administrative expenses   95,839    62,085    244,834    165,425 
Total operating expenses   95,839    62,085    244,834    165,425 
                     
LOSS FROM OPERATIONS   (95,839)   (62,085)   (244,834)   (165,425)
                     
OTHER INCOME (EXPENSE)                    
Interest income (expense)   
-
    2    
-
    3 
Loss on disposal of subsidiary   (192,365)   
-
    (192,365)   
-
 
Foreign currency income (loss)   
-
    4    (43)   6 
Other non-operating income (expenses), net   (750)   (1,145)   (1,500)   (1,895)
Total other (expense) income   (193,115)   (1,139)   (193,908)   (1,886)
                     
Loss before income taxes   (288,954)   (63,224)   (438,742)   (167,311)
                     
Provision for income taxes   
-
    
-
    
-
    
-
 
                     
NET LOSS   (288,954)   (63,224)   (438,742)   (167,311)
                     
OTHER COMPREHENSIVE INCOME (LOSS)                    
Foreign currency transaction adjustments   193,643    6    193,558    (2)
                     
COMPREHENSIVE LOSS  $(95,311)  $(63,218)  $(245,184)  $(167,313)
                     
BASIC & DILUTED LOSS PER SHARE    *      *      *      *  
                     
WEIGHTED AVERAGE NUMBER OF ORGINARY SHARES-BASIC & DILUTED
   473,950,309    299,686,921    385,390,227    299,686,921 

 

*Less than $0.01 per share

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

2

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONDENSED CONSOILDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)

 

   Common Stock   Additional   Discount on       Accumulated Other   Total 
   Number of      Paid-in-   common   Accumulated   Comprehensive   Stockholders’ 
   Shares   Amount   Capital   stock   Deficit   Income (loss)   Equity 
Balance at September 30, 2022 (restated)   299,686,921   $299,687   $16,927,592   $(7,241,581)  $(9,875,489)  $(193,558)  $(83,349)
Foreign currency translation                            (85)   (85)
Stock based compensation (restated)             18,750                   18,750 
Net loss (restated)                       (149,788)        (149,788)
Balance at December 31, 2022 (restated)   299,686,921    299,687    16,946,342    (7,241,581)   (10,025,277)   (193,643)   (214,472)
Common stock issued   375,000,000    375,000    (13,000)                  362,000 
Issuance of common stock for debt conversion   134,213,120    134,213                        134,213 
Stock-based compensation             18,750                   18,750 
Disposal of subsidiary                            193,643    193,643 
Net loss                       (288,954)        (288,954)
Balance at March 31, 2023   808,900,041   $808,900   $16,952,092   $(7,241,581)  $(10,314,231)  $
-
   $205,180 

 

                   Accumulated     
   Common Stock   Additional   Discount on       Other   Total 
   Number of      Paid-in-   common   Accumulated   Comprehensive   Stockholders’ 
   Shares   Amount   Capital   stock   Deficit   Income (loss)   Equity 
Balance at September 30, 2021   299,686,921   $299,687   $16,911,770   $(7,241,581)  $(9,522,821)  $(193,583)  $253,472 
Foreign currency translation                            (8)   (8)
Net loss                       (104,087)        (104,087)
Balance at December 31, 2021   299,686,921    299,687    16,911,770    (7,241,581)   (9,626,908)   (193,591)   149,377 
Foreign currency translation                            6    6 
Net loss                       (63,224)        (63,224)
Balance at March 31, 2022   299,686,921   $299,687   $16,911,770   $(7,241,581)  $(9,690,132)  $(193,585)  $86,159 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

   For the Six Months Ended March 31, 
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss  $(438,742)  $(167,311)
Adjustments to reconcile net loss to net cash used in operating activities          
Stock-based compensation   37,500    
-
 
Loss on disposal of subsidiary   192,365    
-
 
Change in operating assets and liabilities          
Prepayment   4,956    4,887 
Accounts payable   323    (3,307)
Accrued expenses   40    (1,590)
Due to related parties   34,958    49,515 
Commitment and contingencies   1,500    1,500 
Net cash used in operating activities   (167,100)   (116,306)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of equipment   (20,167)   
-
 
Proceeds from sale of Hukui investment   
-
    350,000 
Net cash (used in) provided by financing activities   (20,167)   350,000 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from issuance of common stock   362,000    
-
 
Net cash provided by financing activities   362,000    
-
 
           
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   174,733    233,694 
           
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD   136,400    9,271 
           
CASH AND CASH EQUIVALENTS - END OF PERIOD  $311,133   $242,965 
           
SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION          
Cash paid for interest  $
-
   $
-
 
Cash paid for income taxes  $
-
   $
-
 
           
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Issuance of common stock for debt conversion  $134,213   $
-
 

 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

 

4

 

 

GENUFOOD ENERGY ENZYMES CORP

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

 

NOTE 1 – GENERAL ORGANIZATION AND BUSINESS

 

Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which has been dissolved on January 9, 2023.

 

Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the six months ended March 31, 2023, the Company has initiated its electric vehicle charging station business.

 

The Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

 

On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

 

On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.

 

As of March 31, 2023, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging Stations at the three confirmed sites. As of March 31, 2023, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.

 

As of February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities.

 

5

 

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The Company’s condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022. 

 

Principle of Consolidation

 

The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

 

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of March 31, 2023 and September 30, 2022, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.

 

6

 

 

Fair Value of Financial Instruments

 

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

  Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.
     
  Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.
     
  Level 3 inputs are less observable and reflect our own assumptions.

 

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

 

Foreign Currency Translation and Transactions

 

The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

 

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for the six months ended March 31, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying condensed consolidated statements of operations.

 

Business Segments

 

The Company operates in only one segment.

 

Net Income (Loss) Per Share

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the six months ended March 31, 2023 and 2022.

 

7

 

 

Discounts on Common Stock

 

Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.

 

Stock-Based Compensation

 

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

 

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

 

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

 

There were no current and deferred income tax provision recorded for the six months ended March 31, 2023 and 2022 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.

 

8

 

 

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

 

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

 

NOTE 3 – GOING CONCERN

 

As of March 31, 2023 and September 30, 2022, the Company had an accumulated deficit of $10,314,231 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

 

The Company sold the 140,000 Hukui Shares for $350,000 in cash on November 19, 2021. The proceeds have been used for operation expenses. Management is currently seeking additional funds for future operation.

 

NOTE 4 – EQUIPMENT

 

As of March 31, 2023, and September 30, 2022 the Company had equipment of $20,167 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations.

 

NOTE 5 – INVESTMENT

 

Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment was recorded at cost.

 

On November 17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.

 

NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

  

Stock Options

 

On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of March 31, 2023, total options granted was 15,000,000 and none was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.

 

9

 

 

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $37,500 and $0, respectively, which was included in the general and administrative expenses in the condensed consolidated statements of operations for the six months ended March 31, 2023 and 2022.

 

The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions: 

 

   March 31,
2023
 
Risk-free interest rate   2.99%
Expected term   6.08 years 
Expected volatility   379.35%
Expected dividend yield   0%

 

The following is a summary of the option activity for the six months ended March 31, 2023:

 

Options  Number of Underlying
Shares
   Weighted
average
exercise
price
   Weighted
Average
Remaining
Contractual
Life (years)
   Aggregate
Intrinsic
Value
 
Outstanding at October 1, 2022   15,000,000   $0.01    
   $
 
Granted   
   $
    
   $
 
Exercised   
   $
    
   $
 
Forfeited or expired   
   $
    
   $
 
Outstanding at March 31, 2023   15,000,000   $0.01    9.3   $225,000 
Vested and expected to vest as of March 31, 2023   15,000,000   $0.01    9.3   $225,000 
Exercisable at March 31, 2023   
   $
    
   $
 

 

As of March 31, 2023, unrecognized total compensation cost associated with these options was $246,678. This expense is expected to be recognized over a weighted-average period of 3.29 years.

 

10

 

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Related Parties

 

Name of related parties   Relationship with the Company
Yi Lung (Oliver) Lin   Principal shareholder
Jui Pin (John) Lin   Principal shareholder, Director, Former President and Chief Executive Officer
Jia Tian (Jeffery) Lin   Former Chief Executive Officer
Wen-Piao (Jack) Lai   Director, Former President and Chief Executive Officer
Shao-Cheng (Will) Wang   Chief Financial Officer
Kuang Ming (James) Tsai   Director
Nan-Yao (Jake) Chan   Former Director 
Hsin-Ta (Darren) Su   Director, Treasurer
Hui-Chuan (Sandra) Lin   Director and Secretary, daughter of Jui Pin (John) Lin

 

Due to Related Parties

 

The Company’s due to related parties balances are as follows:

 

   March 31,
2023
   September 30,
2022
 
Kuang Ming (James) Tsai  $
-
   $20,755 
Jui Pin (John) Lin   
-
    8,048 
Jia Tian (Jeffery) Lin   
-
    2,500 
Shao-Cheng (Will) Wang   
-
    27,600 
Wen-Piao (Jack) Lai   
-
    22,210 
Hsin-Ta (Darren) Su   550    17,189 
Hui-Chuan (Sandra) Lin   
-
    4,529 
David Tang   4,226    
-
 
Total  $4,776   $102,831 

 

The related party balances are unsecured, interest-free and due on demand.

 

NOTE 8 – INCOME TAXES

 

The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.

 

11

 

 

Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

 

The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $5,726, for a total of $30,726, which was still pending as of March 31, 2023.

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

The Company terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of March 31, 2023, the Company has no material commitments under operating leases.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 8).

 

NOTE 10 – SUBSEQUENT EVENTS

 

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.

 

12

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

 

Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect”, “anticipate”, “hope” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

 

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. Some of the key factors impacting these risks and uncertainties include, but are not limited to:

 

  risks related to our ability to identify, pursue and commence a reverse merger and/or a possible operating business;

 

  our ability to obtain adequate funding to complete a reverse merger or commence a possible operating business and meet our operating expenses on a current basis;

 

  general economic uncertainty, whether as a result of the COVID-19 pandemic or otherwise;

 

  delays in our ability to obtain any necessary business licenses and permits, and commence business operations, whether as a result of the COVID-19 pandemic or otherwise; and

 

  current and longer-term economic and other impacts of the COVID-19 pandemic on our operations, results of operations and financial condition, including without limitation changes in consumer spending patterns for non-essential products, resulting from the economic crisis caused by lockdown, shelter-in-place, stay-at-home or similar orders instituted as a result of the pandemic, or otherwise.

 

Overview

 

On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

 

On October 26, 2022, we entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow us to install our electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, we have agreed to share our revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.

 

13

 

 

As of December 31, 2022, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging Stations at the three confirmed sites. As of December 31, 2022, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.

 

As of February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities. The Company expects to install up to a total of 10 charging units for the first 2 sites, and have them operational in April of 2023.

 

Hukui Investment

 

Hukui Biotechnology Corporation (“Hukui”) and we entered into a Series C Preferred Shares Subscription Agreement dated September 23, 2020 (the “Hukui Agreement”), pursuant to which we agreed to purchase an aggregate 200,000 shares of Hukui’s Series C Preferred Stock (the “Series C Preferred Shares”) at $10.00 per share, for an aggregate investment of $2,000,000.

 

The Hukui Agreement provided that we would purchase the Series C Preferred Shares in three tranches, through a date on or before June 30, 2022, as follows:

 

  The first tranche is 80,000 Series C Preferred Shares in the amount of $800,000 (the “First Tranche Investment”), such shares having been purchased by us on December 15, 2020 (the “First Tranche Closing”);

 

  The second tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Second Tranche Investment”), such shares having been purchased by us on June 25, 2021 (the “Second Tranche Closing”); and

 

  The third tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Third Tranche Investment”), such shares to have been purchased on or before June 30, 2022 (the “Third Tranche Closing”).

 

An individual and resident of the Republic of China (the “Purchaser”), Hukui and we entered into a Stock Purchase Agreement dated as of November 17, 2021 (the “Stock Purchase Agreement”), pursuant to which we agreed to sell the 140,000 shares of Hukui’s Series C Preferred Stock that we had purchased in the First Tranche Closing and the Second Tranche Closing (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

 

On December 17, 2021, Hukui and we entered into an Agreement (the “Termination Agreement”), pursuant to which our obligation to make the Third Tranche Investment was terminated and the Hukui Agreement was terminated. As a result, we have no continuing contractual obligation to make any investment in Hukui.

 

14

 

 

Results of Operations

 

Three-Month Period Ended March 31, 2023 compared to the Three-Month Period Ended March 31, 2022

 

Revenues

 

We did not generate any revenues during the three-month period ended March 31, 2023 and 2022.

 

Operating Expenses

 

We incurred total operating expenses of $95,839 and $62,085 for the three-month periods ended March 31, 2023 and 2022, respectively. Our operating expenses consist of legal fees, other professional fees, payroll expenses, stock-based compensation, rent, bank charges, and transfer agent fees. The increase in operating expenses for the three-month period ended March 31, 2023 compared to the same period ended in 2022 was primarily due to increase in payroll expenses and stock-based compensation.

 

Other expense

 

During the three-month period ended March 31, 2023, we incurred $750 other expenses due to interest incurred for unpaid penalty from IRS. During the three-month period ended March 31, 2022, we incurred $1,145 other expense was mainly due to interest incurred for unpaid penalty from IRS. During the three months ended March 31, 2023, we dissolved our Singapore subsidiary, resulting a loss on disposal of subsidiary of $192,365.

 

Net Loss

 

As a result of the above, our net loss increased from $63,224 in the three-month period ended March 31, 2022 to $288,954 in the same period ended in 2023.

 

Six-Month Period Ended March 31, 2023 compared to the Six-Month Period Ended March 31, 2022

 

Revenues

 

We did not generate any revenues during the six-month periods ended March 31, 2023 and 2022.

 

Operating Expenses

 

We incurred total operating expenses of $244,834 and $165,425 for the six-month periods ended March 31, 2023 and 2022, respectively. Our operating expenses consist of legal fees, other professional fees, payroll expenses, stock-based compensation, rent, bank charges, and transfer agent fees. The increase in operating expenses for the six-month period ended March 31, 2023 compared to the same period ended in 2022 was primarily due to increase in payroll expenses, and stock-based compensation.

 

Other expense

 

During the six-month period ended March 31, 2023, we incurred $1,500 other expenses mainly due to interest incurred for unpaid penalty from IRS. During the six-month period ended March 31, 2022, we incurred $1,895 other expenses mainly due to interest incurred for unpaid penalty from IRS. During the six months ended March 31, 2023, we dissolved our Singapore subsidiary, resulting a loss on disposal of subsidiary of $192,365.

        

Net Loss

 

As a result of the above, our net loss increased from $167,311 in the six-month period ended March 31, 2022 to $438,742 in the same period ended in 2023.

 

Effect of the COVID-19 Pandemic on our Business

 

While our liquidity and capital resources are severely limited and present serious obstacles to starting a business, these limitations are unrelated to the COVID-19 pandemic and resulting global economic crisis.

 

Our personnel are in Taiwan, which has been relatively less affected by the pandemic compared to many other countries in Asia, Europe and the United States. However, even before an increase in the number of cases of COVID-19 in Taiwan, we experienced delays in obtaining business licenses and permits, and any other governmental approvals that might have been required for businesses that we previously considered commencing, since government offices have been working with reduced staff during the pandemic. We expect this situation to continue and possibly become more challenging depending upon the duration of the pandemic.

 

Depending upon the extent and duration of the pandemic and the resulting global economic crisis, these conditions may have an adverse impact on our ability to raise capital and commence any business we may pursue.

 

15

 

 

Liquidity and Capital Resources

 

Working Capital

 

   March 31,   September 30, 
   2023   2022 
Current Assets  $320,670   $150,893 
Current Liabilities   104,931    205,016 
Working Capital (Deficit)  $215,739   $(54,123)

 

As of March 31, 2023, we had current assets of $320,670 and a working surplus of $215,739. In comparison, as of September 30, 2022, we had current assets of $150,893 and a working capital deficit of $54,123.

 

As of March 31, 2023, we had total assets of $340,837, compared with total assets of $150,893 at September 30, 2022. The increase in total assets was primarily due to cash received from fundraising.

 

We had $104,931 in total current liabilities as of March 31, 2023, consisting of $100,115 in accounts payable, $40 in accrued expenses and $4,776 due to related parties. This is compared to total current liabilities of $205,016 in total current liabilities as of September 30, 2022, consisting of $102,185 in accounts payable and $102,831 due to related parties. The decrease in due to related parties was primarily due to unpaid compensation to officers and directors repaid by shares.

 

We had total stockholders’ equity of $205,180 and an accumulated deficit of $10,314,231 as of March 31, 2023. In comparison, we had a total stockholders’ deficit of $83,349 and an accumulated deficit of $9,875,489 as of September 30, 2022.

 

Cash Flows

 

   Six Months Ended
March 31,
2023
   Six Months Ended
March 31,
2022
 
Cash flows used in operating activities  $(167,100)  $(116,306)
Cash flows (used in) provided by investing activities   (20,167)   350,000 
Cash flows provided by financing activities   362,000    - 
Net increase in cash during period  $174,733   $233,694 

 

During the six months ended March 31, 2023, we used $167,100 of cash in operating activities which was attributable primarily to our net loss of $438,742 offset by loss on disposal of subsidiary, stock-based compensation, and change in operating assets and liabilities of $271,642. In comparison, during the six months ended March 31, 2022, we used $116,306 of cash in operating activities which was attributable primarily to our net loss of $167,311 offset by change in operating assets and liabilities of $51,005.

 

During the six months ended March 31, 2023, we used $20,167 of cash investing activity in purchase of equipment. We received $350,000 in payment for the sale of the 140,000 Hukui Shares during the six months ended March 31, 2022.

 

During the six months ended March 31, 2023 we received $362,000, net of directly associated legal expenses from private offering of our Common Stock. During the six months ended March 31, 2022, we did not have any financing activity.

 

There is substantial doubt that we can continue as an ongoing business for the next twelve months unless we obtain additional capital to pay our expenses as they become due. We do not anticipate any significant additional revenue until and unless we begin to execute on our plan of operations involving the start of our new electric vehicle charging station business. There is no assurance that we will ever reach that stage. The condensed consolidated financial statements presented herein do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that we cannot continue as a going concern.

 

16

 

 

Our ability to continue as a going concern is dependent upon our ability to successfully execute our business plan and generate profitable operations in the future, and, until and unless we achieve that, to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operation as and when they become due. To date, our capital requirements have primarily been funded by shareholders through the purchase of our Common Stock in private offerings and short-term borrowings from a former officer and another shareholder.

 

The Company sold the 140,000 Hukui Shares for $350,000 cash on November 19, 2021. The proceeds have been used for operation expenses.

 

Contractual Obligations

 

We do not have material contractual obligations and commitments. We only have one lease that is renewed on a month-to-month basis.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2023, we had not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. As of March 31, 2023, we had not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our condensed consolidated financial statements. Furthermore, as of March 31, 2023, we had not had any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. As of March 31, 2023, we had not had any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

 

Critical accounting policies and estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to income taxes, and the valuation of equity transactions. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. For the six months ended March 31, 2023 and 2022, no significant estimates and assumptions have been made in the condensed consolidated financial statements. The following are some of the critical accounting policies in relation to the preparation of the condensed consolidated financial statements. For a full summary of our critical accounting policies, please refer to Note 2 to the Condensed Consolidated Financial Statements.

 

Stock-Based Compensation

 

We account for stock-based compensation in which we obtain employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires us to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

  

Recent accounting pronouncements

 

We do not expect that the adoption of recently issued accounting pronouncements will have a material impact on our financial position, results of operations, or cash flows. For a full summary of recent accounting pronouncements, please refer to Note 2 to the Condensed Consolidated Financial Statements. 

 

Currency exchange rates

 

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022, respectively. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for the six months ended March 31, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit. 

17

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK.

 

Not required for smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that the information relating to our Company, including our consolidated subsidiary, required to be disclosed in our reports filed with the Securities and Exchange Commission (the “SEC”) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of the evaluation date, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting, as described below.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of management, including our chief executive officer and chief financial officer, we conducted an evaluation of the design and operating effectiveness of our internal controls over financial reporting based on the framework in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

 

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2023 and identified the following material weaknesses:

 

Inadequate Segregation of Duties: We have an inadequate number of personnel to properly implement control procedures.

 

Comingling of funds: We do not have adequate control of our petty cash, resulting in the comingling of our petty cash with the nominal account holder’s personal funds.

 

Lack of Adequate Staffing: We do not have adequate in-house accounting personnel and expertise in key positions, which resulted in overly relying on outside consultants in preparing financial statements and other required disclosures by the Securities and Exchange Commission.

 

Ineffective oversight: We do not exercise effective oversight and monitoring procedures designed and implemented to certain control activities.

 

Overly relied on outside professionals: We are unable to prepare internally financial statements and relied on outside professional consultants to prepare financial statements and adequate disclosures.

 

18

 

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As a result of the material weaknesses in internal control over financial reporting identified above, management concluded that the Company’s internal control over financial reporting was not effective as of March 31, 2023  based on the criteria set forth in “Internal Control-Integrated Framework” issued by COSO.

 

Due to the nature of the material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected. The material weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s condensed consolidated financial statements at and for the three-month periods ended March 31, 2023.

 

Management’s Plan for Remediation

 

Management has discussed the material weaknesses noted above with our independent registered public accounting firm. Management is committed to improving its internal controls and, subject to having adequate financial resources, intends to:

 

  increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties to monitor and review until there are sufficient personnel to segregate duties;

 

  consider providing professional courses for our key position personnel;

 

  hire additional employees to realize segregation of duties; and

 

  strengthen management monitoring control over accounting and financial statements preparation processing.

 

However, due to limitation of funds and personnel, we have so far been unable to begin to implement the plan to remediate the material weaknesses noted above and it is uncertain when we will be able to begin to implement the plan to remediate these material weaknesses.

 

Inherent Limitations on Effectiveness of Controls

 

A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect all control issues or misstatements. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become adequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Changes in Internal Control

 

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

19

 

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not currently a party to any lawsuit or proceeding, which, in the opinion of management, is likely to have a material adverse effect on us or our business.

 

ITEM 1A. RISK FACTORS

 

Not required of smaller reporting companies.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

On February 24, 2023 (the “Closing Date”), GenuFood Energy Enzymes Corp. (the “Company”) entered into a Subscription Agreement with each of certain subscribers (each, a “Purchaser” and collectively, the “Purchasers”) who have subscribed to purchase a certain amount of shares of common stock of the Company, par value 0.001 (the “Common Stock”), as set forth in that respective purchasers Subscription Agreement, each subscribing for not less than $5,000 and up to 5,000,000 shares at a purchase price of US$0.001 per share. The Company was conducting this private offering (the “Offering”) pursuant to a private placement memorandum (the “PPM”) whereby the Company was offering and selling a minimum amount of $500,000 (the “Minimum Offering Amount”) and maximum of $1,000,000 of its common shares to accredited investors and non-U.S. persons. The gross proceeds from the private placement were $375,000.00.

 

The shares of Common Stock issued and sold under the Subscription Agreement as described above were offered and sold by the Company in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D thereunder.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None. 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

20

 

 

ITEM 6. EXHIBITS

 

Exhibit No.   Description
31.1   Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
31.2   Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
32.1*   Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*   Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* The certifications attached as Exhibits 32.1 and 32.2 accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

21

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GENUFOOD ENERGY ENZYMES CORP.
     
Date: June 2, 2023 By: /s/ David Tang
    David Tang
    Chief Executive Officer
   
  By: /s/ Shao-Cheng Wang
    Shao-Cheng Wang
    Chief Financial Officer

 

 

22

 

--09-30 Genufood Energy Enzymes Corp. NONE Yes 68-0681158 Yes 299686921 299686921 385390227 473950309 false Q2 false 0001510518 0001510518 2022-10-01 2023-03-31 0001510518 2023-03-31 0001510518 2022-09-30 0001510518 2023-01-01 2023-03-31 0001510518 2022-01-01 2022-03-31 0001510518 2021-10-01 2022-03-31 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001510518 2022-10-01 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001510518 us-gaap:CommonStockMember 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001510518 2022-12-31 0001510518 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001510518 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001510518 us-gaap:CommonStockMember 2023-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2023-03-31 0001510518 us-gaap:RetainedEarningsMember 2023-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0001510518 2021-10-01 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001510518 us-gaap:CommonStockMember 2021-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001510518 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001510518 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001510518 us-gaap:CommonStockMember 2022-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-03-31 0001510518 us-gaap:RetainedEarningsMember 2022-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001510518 2022-03-31 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2022-09-01 2022-09-30 0001510518 gfoo:HukuiBiotechnologyCorporationMember 2021-11-19 0001510518 2021-11-01 2021-11-19 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-19 2021-11-19 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 us-gaap:StockOptionMember 2022-10-01 2023-03-31 0001510518 us-gaap:StockOptionMember 2022-09-01 2022-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2023-03-31 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2023-03-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2023-03-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2023-03-31 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2023-03-31 0001510518 gfoo:NanYaoJakeChanMember 2022-10-01 2023-03-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2023-03-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2023-03-31 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2023-03-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2023-03-31 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2023-03-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2023-03-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2023-03-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:DavidTangMember 2023-03-31 0001510518 gfoo:DavidTangMember 2022-09-30 0001510518 2019-10-01 2020-09-30 0001510518 2023-03-29 2023-03-31 0001510518 2020-10-01 2021-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0323ex31-1_genu.htm CERTIFICATION

 Exhibit 31.1

 

CERTIFICATION

 

I, David Tang, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Genufood Energy Enzymes Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 2, 2023  
   
By: /s/ David Tang  
Name: David Tang  
Title: Chief Executive Officer  
(principal executive officer  

  

 

EX-31.2 3 f10q0323ex31-2_genu.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION

 

I, Shao-Cheng Wang, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Genufood Energy Enzymes Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 2, 2023  
   
By: /s/ Shao-Cheng Wang  
Name: Shao-Cheng Wang  
Title: Chief Financial Officer  
(principal financial officer and
principal accounting officer)
 

 

 

 

EX-32.1 4 f10q0323ex32-1_genu.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION

 

In connection with the quarterly report of Genufood Energy Enzymes Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, David Tang, Chief Executive Officer (Principal Executive Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

Date: June 2, 2023  
   
By: /s/ David Tang  
Name: David Tang  
Title: Chief Executive Officer  
(principal executive officer)  

 

This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 f10q0323ex32-2_genu.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION

 

In connection with the quarterly report of Genufood Energy Enzymes Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Shao-Cheng Wang, Chief Financial Officer (Principal Financial Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

Date: June 2, 2023  
   
By: /s/ Shao-Cheng Wang  
Name: Shao-Cheng Wang  
Title: Chief Financial Officer  
(principal financial officer and
principal accounting officer)
 

 

This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EX-101.SCH 6 gfoo-20230331.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consoildated Statements of Stockholders’ Equity (Deficit) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - General Organization and Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Equipment link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Investment link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stockholders’ Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Stockholders’ Equity (Deficit) (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - General Organization and Business (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Investment (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Stockholders’ Equity (Deficit) (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Stockholders’ Equity (Deficit) (Details) - Schedule of fair value the stock options black-scholes option pricing model link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Stockholders’ Equity (Deficit) (Details) - Schedule of stock options link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Related Party Transactions (Details) - Schedule of related parties transactions link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties balances link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 gfoo-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 gfoo-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 gfoo-20230331_lab.xml XBRL LABEL FILE EX-101.PRE 10 gfoo-20230331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
6 Months Ended
Mar. 31, 2023
shares
Document Information Line Items  
Entity Registrant Name Genufood Energy Enzymes Corp.
Trading Symbol N/A
Document Type 10-Q
Current Fiscal Year End Date --09-30
Entity Common Stock, Shares Outstanding 808,900,041
Amendment Flag false
Entity Central Index Key 0001510518
Entity Current Reporting Status Yes
Entity Filer Category Non-accelerated Filer
Document Period End Date Mar. 31, 2023
Document Fiscal Year Focus 2023
Document Fiscal Period Focus Q2
Entity Small Business true
Entity Emerging Growth Company false
Entity Shell Company false
Document Quarterly Report true
Entity File Number 000-56112
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 1108 S. Baldwin Avenue
Entity Address, Address Line Two Suite 107
Entity Address, City or Town Arcadia
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91007
City Area Code (855)
Local Phone Number 707-2077
Title of 12(b) Security N/A
Security Exchange Name NONE
Entity Tax Identification Number 68-0681158
Entity Interactive Data Current Yes
Document Transition Report false
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2023
Sep. 30, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 311,133 $ 136,400
Prepayment 9,537 14,493
Total Current Assets 320,670 150,893
Equipment 20,167
Total Assets 340,837 150,893
CURRENT LIABILITIES    
Accounts payable 100,115 102,185
Accrued expenses 40
Due to related parties 4,776 102,831
Total Current Liabilities 104,931 205,016
Commitment and contingencies (Note 9) 30,726 29,226
STOCKHOLDERS’ EQUITY (DEFICIT)    
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively 808,900 299,687
Additional paid-in capital 16,952,092 16,927,592
Discount on common stock (7,241,581) (7,241,581)
Accumulated deficit (10,314,231) (9,875,489)
Accumulated other comprehensive loss (193,558)
Total Stockholders’ Equity (Deficit) 205,180 (83,349)
Total Liabilities and Stockholders’ Equity $ 340,837 $ 150,893
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Mar. 31, 2023
Sep. 30, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 10,000,000,000 10,000,000,000
Common stock, shares issued 808,900,041 299,686,921
Common stock, shares outstanding 808,900,041 299,686,921
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]        
REVENUE
OPERATING EXPENSES        
General and administrative expenses 95,839 62,085 244,834 165,425
Total operating expenses 95,839 62,085 244,834 165,425
LOSS FROM OPERATIONS (95,839) (62,085) (244,834) (165,425)
OTHER INCOME (EXPENSE)        
Interest income (expense) 2 3
Loss on disposal of subsidiary (192,365) (192,365)
Foreign currency income (loss) 4 (43) 6
Other non-operating income (expenses), net (750) (1,145) (1,500) (1,895)
Total other (expense) income (193,115) (1,139) (193,908) (1,886)
Loss before income taxes (288,954) (63,224) (438,742) (167,311)
Provision for income taxes
NET LOSS (288,954) (63,224) (438,742) (167,311)
OTHER COMPREHENSIVE INCOME (LOSS)        
Foreign currency transaction adjustments 193,643 6 193,558 (2)
COMPREHENSIVE LOSS $ (95,311) $ (63,218) $ (245,184) $ (167,313)
BASIC & DILUTED LOSS PER SHARE (in Dollars per share) [1]
WEIGHTED AVERAGE NUMBER OF ORGINARY SHARES-BASIC & DILUTED (in Shares) 473,950,309 299,686,921 385,390,227 299,686,921
[1] Less than $0.01 per share
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]        
DILUTED LOSS PER SHARE
WEIGHTED AVERAGE NUMBER OF COMMON STOCKS-DILUTED 473,950,309 299,686,921 385,390,227 299,686,921
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consoildated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Common Stock
Additional Paid-in-Capital
Discount on common stock
Accumulated Deficit
Accumulated Other Comprehensive Income (loss)
Total
Balance at Sep. 30, 2021 $ 299,687 $ 16,911,770 $ (7,241,581) $ (9,522,821) $ (193,583) $ 253,472
Balance (in Shares) at Sep. 30, 2021 299,686,921          
Foreign currency translation         (8) (8)
Net loss       (104,087)   (104,087)
Balance at Dec. 31, 2021 $ 299,687 16,911,770 (7,241,581) (9,626,908) (193,591) 149,377
Balance (in Shares) at Dec. 31, 2021 299,686,921          
Balance at Sep. 30, 2021 $ 299,687 16,911,770 (7,241,581) (9,522,821) (193,583) 253,472
Balance (in Shares) at Sep. 30, 2021 299,686,921          
Net loss           (167,311)
Balance at Mar. 31, 2022 $ 299,687 16,911,770 (7,241,581) (9,690,132) (193,585) 86,159
Balance (in Shares) at Mar. 31, 2022 299,686,921          
Balance at Dec. 31, 2021 $ 299,687 16,911,770 (7,241,581) (9,626,908) (193,591) 149,377
Balance (in Shares) at Dec. 31, 2021 299,686,921          
Foreign currency translation         6 6
Net loss       (63,224)   (63,224)
Balance at Mar. 31, 2022 $ 299,687 16,911,770 (7,241,581) (9,690,132) (193,585) 86,159
Balance (in Shares) at Mar. 31, 2022 299,686,921          
Balance at Sep. 30, 2022 $ 299,687 16,927,592 (7,241,581) (9,875,489) (193,558) (83,349)
Balance (in Shares) at Sep. 30, 2022 299,686,921          
Foreign currency translation         (85) (85)
Stock-based compensation   18,750       18,750
Net loss       (149,788)   (149,788)
Balance at Dec. 31, 2022 $ 299,687 16,946,342 (7,241,581) (10,025,277) (193,643) (214,472)
Balance (in Shares) at Dec. 31, 2022 299,686,921          
Balance at Sep. 30, 2022 $ 299,687 16,927,592 (7,241,581) (9,875,489) (193,558) (83,349)
Balance (in Shares) at Sep. 30, 2022 299,686,921          
Net loss           (438,742)
Balance at Mar. 31, 2023 $ 808,900 16,952,092 (7,241,581) (10,314,231) 205,180
Balance (in Shares) at Mar. 31, 2023 808,900,041          
Balance at Dec. 31, 2022 $ 299,687 16,946,342 (7,241,581) (10,025,277) (193,643) (214,472)
Balance (in Shares) at Dec. 31, 2022 299,686,921          
Common stock issued $ 375,000 (13,000)       362,000
Common stock issued (in Shares) 375,000,000          
Issuance of common stock for debt conversion $ 134,213         134,213
Issuance of common stock for debt conversion (in Shares) 134,213,120          
Disposal of subsidiary         193,643 193,643
Stock-based compensation   18,750       18,750
Net loss       (288,954)   (288,954)
Balance at Mar. 31, 2023 $ 808,900 $ 16,952,092 $ (7,241,581) $ (10,314,231) $ 205,180
Balance (in Shares) at Mar. 31, 2023 808,900,041          
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (438,742) $ (167,311)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 37,500
Loss on disposal of subsidiary 192,365
Change in operating assets and liabilities    
Prepayment 4,956 4,887
Accounts payable 323 (3,307)
Accrued expenses 40 (1,590)
Due to related parties 34,958 49,515
Commitment and contingencies 1,500 1,500
Net cash used in operating activities (167,100) (116,306)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of equipment (20,167)
Proceeds from sale of Hukui investment 350,000
Net cash (used in) provided by financing activities (20,167) 350,000
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from issuance of common stock 362,000
Net cash provided by financing activities 362,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 174,733 233,694
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 136,400 9,271
CASH AND CASH EQUIVALENTS - END OF PERIOD 311,133 242,965
SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION    
Cash paid for interest
Cash paid for income taxes
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Issuance of common stock for debt conversion $ 134,213
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
General Organization and Business
6 Months Ended
Mar. 31, 2023
General Organization and Business [Abstract]  
GENERAL ORGANIZATION AND BUSINESS

NOTE 1 – GENERAL ORGANIZATION AND BUSINESS

 

Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which has been dissolved on January 9, 2023.

 

Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the six months ended March 31, 2023, the Company has initiated its electric vehicle charging station business.

 

The Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

 

On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

 

On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.

 

As of March 31, 2023, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging Stations at the three confirmed sites. As of March 31, 2023, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.

 

As of February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
6 Months Ended
Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The Company’s condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022. 

 

Principle of Consolidation

 

The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

 

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of March 31, 2023 and September 30, 2022, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.

 

Fair Value of Financial Instruments

 

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

  Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.
     
  Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.
     
  Level 3 inputs are less observable and reflect our own assumptions.

 

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

 

Foreign Currency Translation and Transactions

 

The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

 

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for the six months ended March 31, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying condensed consolidated statements of operations.

 

Business Segments

 

The Company operates in only one segment.

 

Net Income (Loss) Per Share

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the six months ended March 31, 2023 and 2022.

 

Discounts on Common Stock

 

Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.

 

Stock-Based Compensation

 

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

 

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

 

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

 

There were no current and deferred income tax provision recorded for the six months ended March 31, 2023 and 2022 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.

 

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

 

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern
6 Months Ended
Mar. 31, 2023
Going Concern [Abstract]  
GOING CONCERN

NOTE 3 – GOING CONCERN

 

As of March 31, 2023 and September 30, 2022, the Company had an accumulated deficit of $10,314,231 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

 

The Company sold the 140,000 Hukui Shares for $350,000 in cash on November 19, 2021. The proceeds have been used for operation expenses. Management is currently seeking additional funds for future operation.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Equipment
6 Months Ended
Mar. 31, 2023
Equipment [Abstract]  
EQUIPMENT

NOTE 4 – EQUIPMENT

 

As of March 31, 2023, and September 30, 2022 the Company had equipment of $20,167 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Investment
6 Months Ended
Mar. 31, 2023
Investment [Abstract]  
INVESTMENT

NOTE 5 – INVESTMENT

 

Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment was recorded at cost.

 

On November 17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Deficit)
6 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS’ EQUITY (DEFICIT)

NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

  

Stock Options

 

On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of March 31, 2023, total options granted was 15,000,000 and none was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.

 

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $37,500 and $0, respectively, which was included in the general and administrative expenses in the condensed consolidated statements of operations for the six months ended March 31, 2023 and 2022.

 

The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions: 

 

   March 31,
2023
 
Risk-free interest rate   2.99%
Expected term   6.08 years 
Expected volatility   379.35%
Expected dividend yield   0%

 

The following is a summary of the option activity for the six months ended March 31, 2023:

 

Options  Number of Underlying
Shares
   Weighted
average
exercise
price
   Weighted
Average
Remaining
Contractual
Life (years)
   Aggregate
Intrinsic
Value
 
Outstanding at October 1, 2022   15,000,000   $0.01    
   $
 
Granted   
   $
    
   $
 
Exercised   
   $
    
   $
 
Forfeited or expired   
   $
    
   $
 
Outstanding at March 31, 2023   15,000,000   $0.01    9.3   $225,000 
Vested and expected to vest as of March 31, 2023   15,000,000   $0.01    9.3   $225,000 
Exercisable at March 31, 2023   
   $
    
   $
 

 

As of March 31, 2023, unrecognized total compensation cost associated with these options was $246,678. This expense is expected to be recognized over a weighted-average period of 3.29 years.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
6 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Related Parties

 

Name of related parties   Relationship with the Company
Yi Lung (Oliver) Lin   Principal shareholder
Jui Pin (John) Lin   Principal shareholder, Director, Former President and Chief Executive Officer
Jia Tian (Jeffery) Lin   Former Chief Executive Officer
Wen-Piao (Jack) Lai   Director, Former President and Chief Executive Officer
Shao-Cheng (Will) Wang   Chief Financial Officer
Kuang Ming (James) Tsai   Director
Nan-Yao (Jake) Chan   Former Director 
Hsin-Ta (Darren) Su   Director, Treasurer
Hui-Chuan (Sandra) Lin   Director and Secretary, daughter of Jui Pin (John) Lin

 

Due to Related Parties

 

The Company’s due to related parties balances are as follows:

 

   March 31,
2023
   September 30,
2022
 
Kuang Ming (James) Tsai  $
-
   $20,755 
Jui Pin (John) Lin   
-
    8,048 
Jia Tian (Jeffery) Lin   
-
    2,500 
Shao-Cheng (Will) Wang   
-
    27,600 
Wen-Piao (Jack) Lai   
-
    22,210 
Hsin-Ta (Darren) Su   550    17,189 
Hui-Chuan (Sandra) Lin   
-
    4,529 
David Tang   4,226    
-
 
Total  $4,776   $102,831 

 

The related party balances are unsecured, interest-free and due on demand.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
6 Months Ended
Mar. 31, 2023
Income Taxes [Abstract]  
INCOME TAXES

NOTE 8 – INCOME TAXES

 

The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.

 

Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

 

The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $5,726, for a total of $30,726, which was still pending as of March 31, 2023.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
6 Months Ended
Mar. 31, 2023
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

The Company terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of March 31, 2023, the Company has no material commitments under operating leases.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 8).

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
6 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

 

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Accounting Policies, by Policy (Policies)
6 Months Ended
Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The Company’s condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022. 

 

Principle of Consolidation

Principle of Consolidation

 

The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

 

Use of Estimates

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Concentrations of Credit Risk

Concentrations of Credit Risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of March 31, 2023 and September 30, 2022, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

  Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.
     
  Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.
     
  Level 3 inputs are less observable and reflect our own assumptions.

 

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

 

Foreign Currency Translation and Transactions

Foreign Currency Translation and Transactions

 

The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

 

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for the six months ended March 31, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying condensed consolidated statements of operations.

 

Business Segments

Business Segments

 

The Company operates in only one segment.

 

Net Income (Loss) Per Share

Net Income (Loss) Per Share

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the six months ended March 31, 2023 and 2022.

 

Discounts on Common Stock

Discounts on Common Stock

 

Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.

 

Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

 

Income Taxes

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

 

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

 

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

 

There were no current and deferred income tax provision recorded for the six months ended March 31, 2023 and 2022 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

 

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Deficit) (Tables)
6 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of fair value the stock options black-scholes option pricing model
   March 31,
2023
 
Risk-free interest rate   2.99%
Expected term   6.08 years 
Expected volatility   379.35%
Expected dividend yield   0%

 

Schedule of stock options
Options  Number of Underlying
Shares
   Weighted
average
exercise
price
   Weighted
Average
Remaining
Contractual
Life (years)
   Aggregate
Intrinsic
Value
 
Outstanding at October 1, 2022   15,000,000   $0.01    
   $
 
Granted   
   $
    
   $
 
Exercised   
   $
    
   $
 
Forfeited or expired   
   $
    
   $
 
Outstanding at March 31, 2023   15,000,000   $0.01    9.3   $225,000 
Vested and expected to vest as of March 31, 2023   15,000,000   $0.01    9.3   $225,000 
Exercisable at March 31, 2023   
   $
    
   $
 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Tables)
6 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Schedule of related parties transactions
Name of related parties   Relationship with the Company
Yi Lung (Oliver) Lin   Principal shareholder
Jui Pin (John) Lin   Principal shareholder, Director, Former President and Chief Executive Officer
Jia Tian (Jeffery) Lin   Former Chief Executive Officer
Wen-Piao (Jack) Lai   Director, Former President and Chief Executive Officer
Shao-Cheng (Will) Wang   Chief Financial Officer
Kuang Ming (James) Tsai   Director
Nan-Yao (Jake) Chan   Former Director 
Hsin-Ta (Darren) Su   Director, Treasurer
Hui-Chuan (Sandra) Lin   Director and Secretary, daughter of Jui Pin (John) Lin

 

Schedule of due to related parties balances
   March 31,
2023
   September 30,
2022
 
Kuang Ming (James) Tsai  $
-
   $20,755 
Jui Pin (John) Lin   
-
    8,048 
Jia Tian (Jeffery) Lin   
-
    2,500 
Shao-Cheng (Will) Wang   
-
    27,600 
Wen-Piao (Jack) Lai   
-
    22,210 
Hsin-Ta (Darren) Su   550    17,189 
Hui-Chuan (Sandra) Lin   
-
    4,529 
David Tang   4,226    
-
 
Total  $4,776   $102,831 

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
General Organization and Business (Details) - Series C Preferred Stock [Member] - USD ($)
1 Months Ended
Dec. 15, 2020
Nov. 17, 2021
Jun. 25, 2021
General Organization and Business (Details) [Line Items]      
Purchasing shares 80,000   60,000
Purchasing share value $ 800,000   $ 600,000
Selling shares   140,000  
Cash price   $ 350,000  
Price per share   $ 2.5  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details)
1 Months Ended 6 Months Ended
Sep. 30, 2022
$ / shares
Mar. 31, 2023
Mar. 31, 2022
$ / shares
Summary of Significant Accounting Policies [Abstract]      
Average exchange rates $ 0.697   $ 0.7383
Number of segments   1  
Tax benefit   50.00%  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern (Details) - USD ($)
1 Months Ended
Nov. 19, 2021
Mar. 31, 2023
Sep. 30, 2022
Going Concern (Details) [Line Items]      
Accumulated deficit   $ (10,314,231) $ (9,875,489)
Cash $ 350,000    
Hukui Biotechnology Corporation [Member]      
Going Concern (Details) [Line Items]      
Company sold shares (in Shares) 140,000    
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Equipment (Details) - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Equipment [Abstract]    
Equipment $ 20,167 $ 0
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Investment (Details) - USD ($)
1 Months Ended 6 Months Ended
Nov. 19, 2021
Dec. 15, 2020
Nov. 17, 2021
Jun. 25, 2021
Sep. 23, 2020
Mar. 31, 2023
Sep. 30, 2021
Investment (Details) [Line Items]              
Total investment           $ 1,400,000  
Percentage of equity investment           20.00%  
Loss on sale $ 1,050,000            
Loss of market value             $ 1,050,000
Series C Preferred Shares [Member]              
Investment (Details) [Line Items]              
Share price (in Dollars per share)   $ 10   $ 10      
Purchase shares of stock (in Shares)   80,000          
Purchase price   $ 800,000   $ 600,000      
Purchase of additional shares (in Shares)       60,000      
Selling aggregate shares (in Shares)     140,000        
Selling shares value     $ 350,000        
Hukui Agreement [Member] | Series C Preferred Shares [Member]              
Investment (Details) [Line Items]              
Purchase aggregate shares (in Shares)         200,000    
Share price (in Dollars per share)     $ 2.5   $ 10    
Aggregate investment         $ 2,000,000    
Selling aggregate shares (in Shares)     140,000        
Selling shares value     $ 350,000        
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Deficit) (Details) - USD ($)
1 Months Ended 6 Months Ended
Jul. 15, 2022
Sep. 30, 2022
Mar. 31, 2023
Mar. 31, 2022
Stockholders’ Equity (Deficit) (Details) [Line Items]        
Common stock, shares authorized   10,000,000,000 10,000,000,000  
Common stock, par value   $ 0.001 $ 0.001  
Options to purchase shares     15,000,000  
Vesting percentage     25.00%  
Employment vesting percentage     75.00%  
Stock option period     3 years 3 months 14 days  
Stock-based compensation     $ 37,500 $ 0
Stock option compensation expenses     $ 246,678  
Stock Option [Member]        
Stockholders’ Equity (Deficit) (Details) [Line Items]        
Stock option period     10 years  
Stock price   $ 0.02    
Chief Executive Officer [Member]        
Stockholders’ Equity (Deficit) (Details) [Line Items]        
Options to purchase shares 15,000,000      
Options per share $ 0.01      
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Deficit) (Details) - Schedule of fair value the stock options black-scholes option pricing model
6 Months Ended
Mar. 31, 2023
Schedule Of The Fair Value of the Stock Options Listed above was Determined using the Black Scholes [Abstract]  
Risk-free interest rate 2.99%
Expected term 6 years 29 days
Expected volatility 379.35%
Expected dividend yield 0.00%
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Deficit) (Details) - Schedule of stock options
6 Months Ended
Mar. 31, 2023
USD ($)
$ / shares
shares
Schedule of the Option Activity [Abstract]  
Number of Underlying Shares, Beginning Outstanding | shares 15,000,000
Weighted average exercise price, Beginning Outstanding | $ / shares $ 0.01
Weighted Average Remaining Contractual Life, Beginning Outstanding
Aggregate Intrinsic Value, Beginning Outstanding | $
Number of Underlying Shares, Granted | shares
Weighted average exercise price, Granted | $ / shares
Weighted Average Remaining Contractual Life, Granted
Aggregate Intrinsic Value, Granted | $
Number of Underlying Shares, Exercised | shares
Weighted average exercise price, Exercised | $ / shares
Weighted Average Remaining Contractual Life, Exercised
Aggregate Intrinsic Value, Exercised | $
Number of Underlying Shares, Forfeited or expired | shares
Weighted average exercise price, Forfeited or expired | $ / shares
Weighted Average Remaining Contractual Life, Forfeited or expired
Aggregate Intrinsic Value, Forfeited or expired | $
Number of Underlying Shares, Ending Outstanding | shares 15,000,000
Weighted average exercise price, Ending Outstanding | $ / shares $ 0.01
Weighted Average Remaining Contractual Life (years), Ending Outstanding 9 years 3 months 18 days
Aggregate Intrinsic Value, Ending Outstanding | $ $ 225,000
Number of Underlying Shares Vested and expected to vest | shares 15,000,000
Weighted average exercise price Vested and expected to vest | $ / shares $ 0.01
Weighted Average Remaining Contractual Life (years) Vested and expected to vest 9 years 3 months 18 days
Aggregate Intrinsic Value Vested and expected to vest | $ $ 225,000
Number of Underlying Shares, Exercisable | shares
Weighted average exercise price, Exercisable | $ / shares
Weighted Average Remaining Contractual Life, Exercisable
Aggregate Intrinsic Value, Exercisable | $
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details) - Schedule of related parties transactions
6 Months Ended
Mar. 31, 2023
Yi Lung (Oliver) Lin [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Principal shareholder
Jui Pin (John) Lin [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Principal shareholder, Director, Former President and Chief Executive Officer
Jia Tian (Jeffery) Lin [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Former Chief Executive Officer
Wen-Piao (Jack) Lai [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Director, Former President and Chief Executive Officer
Shao-Cheng (Will) Wang [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Chief Financial Officer
Kuang Ming (James) Tsai [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Director
Nan-Yao (Jake) Chan [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Former Director
Hsin-Ta (Darren) Su [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Director, Treasurer
Hui-Chuan (Sandra) Lin [Member]  
Related Party Transaction [Line Items]  
Relationship with the Company Director and Secretary, daughter of Jui Pin (John) Lin
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details) - Schedule of due to related parties balances - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance $ 4,776 $ 102,831
Kuang Ming (James) Tsai [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance 20,755
Jui Pin (John) Lin [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance 8,048
Jia Tian (Jeffery) Lin [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance 2,500
Shao-Cheng (Will) Wang [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance 27,600
Wen-Piao (Jack) Lai [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance 22,210
Hsin-Ta (Darren) Su [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance 550 17,189
Hui-Chuan (Sandra) Lin [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance 4,529
David Tang [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Due to related party balance $ 4,226
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
12 Months Ended
Mar. 31, 2023
Sep. 30, 2020
Sep. 30, 2021
Income Taxes [Abstract]      
Penalty amount $ 10,000    
Penalty received     $ 25,000
Income taxes return, percentage   25.00%  
Forgiveness of penalty and interest 5,726    
Total amount of penalty and interest $ 30,726    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details) - USD ($)
6 Months Ended 12 Months Ended
Mar. 31, 2023
Sep. 30, 2021
Sep. 30, 2020
Commitments and Contingencies [Abstract]      
Operating lease cost $ 200    
Penalty imposed   $ 25,000  
Information return percentage     25.00%
XML 43 f10q0323_genufood_htm.xml IDEA: XBRL DOCUMENT 0001510518 2022-10-01 2023-03-31 0001510518 2023-03-31 0001510518 2022-09-30 0001510518 2023-01-01 2023-03-31 0001510518 2022-01-01 2022-03-31 0001510518 2021-10-01 2022-03-31 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001510518 2022-10-01 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001510518 us-gaap:CommonStockMember 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001510518 2022-12-31 0001510518 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001510518 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001510518 us-gaap:CommonStockMember 2023-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2023-03-31 0001510518 us-gaap:RetainedEarningsMember 2023-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0001510518 2021-10-01 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001510518 us-gaap:CommonStockMember 2021-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001510518 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001510518 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001510518 us-gaap:CommonStockMember 2022-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-03-31 0001510518 us-gaap:RetainedEarningsMember 2022-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001510518 2022-03-31 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2022-09-01 2022-09-30 0001510518 gfoo:HukuiBiotechnologyCorporationMember 2021-11-19 0001510518 2021-11-01 2021-11-19 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-19 2021-11-19 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 us-gaap:StockOptionMember 2022-10-01 2023-03-31 0001510518 us-gaap:StockOptionMember 2022-09-01 2022-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2023-03-31 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2023-03-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2023-03-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2023-03-31 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2023-03-31 0001510518 gfoo:NanYaoJakeChanMember 2022-10-01 2023-03-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2023-03-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2023-03-31 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2023-03-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2023-03-31 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2023-03-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2023-03-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2023-03-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:DavidTangMember 2023-03-31 0001510518 gfoo:DavidTangMember 2022-09-30 0001510518 2019-10-01 2020-09-30 0001510518 2023-03-29 2023-03-31 0001510518 2020-10-01 2021-09-30 shares iso4217:USD iso4217:USD shares pure 10-Q true 2023-03-31 2023 000-56112 NV 1108 S. Baldwin Avenue Suite 107 Arcadia CA 91007 (855) 707-2077 N/A N/A Non-accelerated Filer true false false 808900041 311133 136400 9537 14493 320670 150893 20167 340837 150893 100115 102185 40 4776 102831 104931 205016 30726 29226 0.001 0.001 10000000000 10000000000 808900041 808900041 299686921 299686921 808900 299687 16952092 16927592 -7241581 -7241581 -10314231 -9875489 -193558 205180 -83349 340837 150893 95839 62085 244834 165425 95839 62085 244834 165425 -95839 -62085 -244834 -165425 2 3 -192365 -192365 4 -43 6 -750 -1145 -1500 -1895 -193115 -1139 -193908 -1886 -288954 -63224 -438742 -167311 -288954 -63224 -438742 -167311 -193643 -6 -193558 2 -95311 -63218 -245184 -167313 473950309 299686921 385390227 299686921 299686921 299687 16927592 -7241581 -9875489 -193558 -83349 -85 -85 18750 18750 -149788 -149788 299686921 299687 16946342 -7241581 -10025277 -193643 -214472 375000000 375000 -13000 362000 134213120 134213 134213 18750 18750 193643 193643 -288954 -288954 808900041 808900 16952092 -7241581 -10314231 205180 299686921 299687 16911770 -7241581 -9522821 -193583 253472 -8 -8 -104087 -104087 299686921 299687 16911770 -7241581 -9626908 -193591 149377 6 6 -63224 -63224 299686921 299687 16911770 -7241581 -9690132 -193585 86159 -438742 -167311 37500 -192365 -4956 -4887 323 -3307 40 -1590 34958 49515 1500 1500 -167100 -116306 20167 350000 -20167 350000 362000 362000 174733 233694 136400 9271 311133 242965 134213 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>NOTE 1 – GENERAL ORGANIZATION AND BUSINESS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which has been dissolved on January 9, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the six months ended March 31, 2023, the Company has initiated its electric vehicle charging station business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of March 31, 2023, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging Stations at the three confirmed sites. As of March 31, 2023, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities.</p> 80000 800000 60000 600000 140000 350000 2.5 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Basis of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company’s condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Principle of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Cash and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of March 31, 2023 and September 30, 2022, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.25in; font-size: 10pt">●</td> <td style="font-size: 10pt; text-align: justify">Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">●</td> <td style="font-size: 10pt; text-align: justify">Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">●</td> <td style="font-size: 10pt; text-align: justify">Level 3 inputs are less observable and reflect our own assumptions.</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Foreign Currency Translation and Transactions</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for the six months ended March 31, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying condensed consolidated statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Business Segments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company operates in only one segment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Net Income (Loss) Per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the six months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Discounts on Common Stock</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Stock-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">There were no current and deferred income tax provision recorded for the six months ended March 31, 2023 and 2022 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Recent Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Basis of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company’s condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Principle of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Cash and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of March 31, 2023 and September 30, 2022, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.25in; font-size: 10pt">●</td> <td style="font-size: 10pt; text-align: justify">Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">●</td> <td style="font-size: 10pt; text-align: justify">Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">●</td> <td style="font-size: 10pt; text-align: justify">Level 3 inputs are less observable and reflect our own assumptions.</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Foreign Currency Translation and Transactions</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for the six months ended March 31, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying condensed consolidated statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.697 0.7383 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Business Segments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company operates in only one segment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Net Income (Loss) Per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the six months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Discounts on Common Stock</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Stock-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">There were no current and deferred income tax provision recorded for the six months ended March 31, 2023 and 2022 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"> </span></p> 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Recent Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 3 – GOING CONCERN</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of March 31, 2023 and September 30, 2022, the Company had an accumulated deficit of $10,314,231 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company sold the 140,000 Hukui Shares for $350,000 in cash on November 19, 2021. The proceeds have been used for operation expenses. Management is currently seeking additional funds for future operation.</span></p> -10314231 -9875489 140000 350000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 4 – EQUIPMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of March 31, 2023, and September 30, 2022 the Company had equipment of $20,167 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations.</p> 20167 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 5 – INVESTMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment was recorded at cost.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On November 17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.</span></p> 200000 10 2000000 80000 10 800000 60000 10 600000 1400000 0.20 140000 2.5 350000 1050000 1050000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Stock Options</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of March 31, 2023, total options granted was 15,000,000 and none was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $37,500 and $0, respectively, which was included in the general and administrative expenses in the condensed consolidated statements of operations for the six months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions: </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.99</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.08 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379.35</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The following is a summary of the option activity for the six months ended March 31, 2023:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Underlying<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at October 1, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">–</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">–</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">–</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">–</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">9.3</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,000</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">9.3</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,000</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of March 31, 2023<i>,</i> unrecognized total compensation cost associated with these options was $246,678. This expense is expected to be recognized over a weighted-average period of 3.29 years.</span></p> 10000000000 0.001 15000000 0.01 15000000 0.25 0.75 P10Y 0.02 37500 0 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.99</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.08 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379.35</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.0299 P6Y29D 3.7935 0 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Underlying<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at October 1, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">–</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">–</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">–</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">–</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">9.3</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,000</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">9.3</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,000</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 15000000 0.01 15000000 0.01 P9Y3M18D 225000 15000000 0.01 P9Y3M18D 225000 246678 P3Y3M14D <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 7 – RELATED PARTY TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b><i>Related Parties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 30%"><b>Name of related parties</b></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 69%"><b>Relationship with the Company</b></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Yi Lung (Oliver) Lin</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: top">Principal shareholder</td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Jui Pin (John) Lin</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Principal shareholder, Director, Former President and Chief Executive Officer</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Jia Tian (Jeffery) Lin</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Former Chief Executive Officer</td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Wen-Piao (Jack) Lai</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Director, Former President and Chief Executive Officer</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Shao-Cheng (Will) Wang</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Chief Financial Officer</td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Kuang Ming (James) Tsai</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: top">Director</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Nan-Yao (Jake) Chan</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Former Director </td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Hsin-Ta (Darren) Su</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Director, Treasurer</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Hui-Chuan (Sandra) Lin</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Director and Secretary, daughter of Jui Pin (John) Lin</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Due to Related Parties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company’s due to related parties balances are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Kuang Ming (James) Tsai</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,755</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jui Pin (John) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jia Tian (Jeffery) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Shao-Cheng (Will) Wang</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Wen-Piao (Jack) Lai</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hsin-Ta (Darren) Su</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,189</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hui-Chuan (Sandra) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">David Tang</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,226</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,776</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102,831</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The related party balances are unsecured, interest-free and due on demand.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 30%"><b>Name of related parties</b></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 69%"><b>Relationship with the Company</b></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Yi Lung (Oliver) Lin</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: top">Principal shareholder</td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Jui Pin (John) Lin</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Principal shareholder, Director, Former President and Chief Executive Officer</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Jia Tian (Jeffery) Lin</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Former Chief Executive Officer</td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Wen-Piao (Jack) Lai</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Director, Former President and Chief Executive Officer</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Shao-Cheng (Will) Wang</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Chief Financial Officer</td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Kuang Ming (James) Tsai</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: top">Director</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Nan-Yao (Jake) Chan</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Former Director </td></tr> <tr style="background-color: White"> <td style="vertical-align: top">Hsin-Ta (Darren) Su</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Director, Treasurer</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top">Hui-Chuan (Sandra) Lin</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">Director and Secretary, daughter of Jui Pin (John) Lin</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> Principal shareholder Principal shareholder, Director, Former President and Chief Executive Officer Former Chief Executive Officer Director, Former President and Chief Executive Officer Chief Financial Officer Director Former Director Director, Treasurer Director and Secretary, daughter of Jui Pin (John) Lin <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Kuang Ming (James) Tsai</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,755</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jui Pin (John) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jia Tian (Jeffery) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Shao-Cheng (Will) Wang</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Wen-Piao (Jack) Lai</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hsin-Ta (Darren) Su</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,189</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hui-Chuan (Sandra) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">David Tang</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,226</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,776</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102,831</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> 20755 8048 2500 27600 22210 550 17189 4529 4226 4776 102831 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>NOTE 8 – INCOME TAXES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $5,726, for a total of $30,726, which was still pending as of March 31, 2023.</span></p> 10000 25000 0.25 5726 30726 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 9 – COMMITMENTS AND CONTINGENCIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of March 31, 2023, the Company has no material commitments under operating leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 8).</span></p> 200 25000 0.25 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 10 – SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.</span></p> --09-30 Genufood Energy Enzymes Corp. NONE Yes 68-0681158 Yes 299686921 299686921 385390227 473950309 false Q2 false 0001510518 Less than $0.01 per share EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 99 189 1 true 20 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://geecenzymes.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://geecenzymes.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://geecenzymes.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Sheet http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consoildated Statements of Stockholders??? Equity (Deficit) (Unaudited) Sheet http://geecenzymes.com/role/ShareholdersEquityType2or3 Condensed Consoildated Statements of Stockholders??? Equity (Deficit) (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://geecenzymes.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - General Organization and Business Sheet http://geecenzymes.com/role/GeneralOrganizationandBusiness General Organization and Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Going Concern Sheet http://geecenzymes.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 010 - Disclosure - Equipment Sheet http://geecenzymes.com/role/Equipment Equipment Notes 11 false false R12.htm 011 - Disclosure - Investment Sheet http://geecenzymes.com/role/Investment Investment Notes 12 false false R13.htm 012 - Disclosure - Stockholders??? Equity (Deficit) Sheet http://geecenzymes.com/role/StockholdersEquityDeficit Stockholders??? Equity (Deficit) Notes 13 false false R14.htm 013 - Disclosure - Related Party Transactions Sheet http://geecenzymes.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 014 - Disclosure - Income Taxes Sheet http://geecenzymes.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Commitments and Contingencies Sheet http://geecenzymes.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Subsequent Events Sheet http://geecenzymes.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 017 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://geecenzymes.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 018 - Disclosure - Stockholders??? Equity (Deficit) (Tables) Sheet http://geecenzymes.com/role/StockholdersEquityDeficitTables Stockholders??? Equity (Deficit) (Tables) Tables http://geecenzymes.com/role/StockholdersEquityDeficit 19 false false R20.htm 019 - Disclosure - Related Party Transactions (Tables) Sheet http://geecenzymes.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://geecenzymes.com/role/RelatedPartyTransactions 20 false false R21.htm 020 - Disclosure - General Organization and Business (Details) Sheet http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails General Organization and Business (Details) Details http://geecenzymes.com/role/GeneralOrganizationandBusiness 21 false false R22.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 22 false false R23.htm 022 - Disclosure - Going Concern (Details) Sheet http://geecenzymes.com/role/GoingConcernDetails Going Concern (Details) Details http://geecenzymes.com/role/GoingConcern 23 false false R24.htm 023 - Disclosure - Equipment (Details) Sheet http://geecenzymes.com/role/EquipmentDetails Equipment (Details) Details http://geecenzymes.com/role/Equipment 24 false false R25.htm 024 - Disclosure - Investment (Details) Sheet http://geecenzymes.com/role/InvestmentDetails Investment (Details) Details http://geecenzymes.com/role/Investment 25 false false R26.htm 025 - Disclosure - Stockholders??? Equity (Deficit) (Details) Sheet http://geecenzymes.com/role/StockholdersEquityDeficitDetails Stockholders??? Equity (Deficit) (Details) Details http://geecenzymes.com/role/StockholdersEquityDeficitTables 26 false false R27.htm 026 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of fair value the stock options black-scholes option pricing model Sheet http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable Stockholders??? Equity (Deficit) (Details) - Schedule of fair value the stock options black-scholes option pricing model Details http://geecenzymes.com/role/StockholdersEquityDeficitTables 27 false false R28.htm 027 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of stock options Sheet http://geecenzymes.com/role/ScheduleofstockoptionsTable Stockholders??? Equity (Deficit) (Details) - Schedule of stock options Details http://geecenzymes.com/role/StockholdersEquityDeficitTables 28 false false R29.htm 028 - Disclosure - Related Party Transactions (Details) - Schedule of related parties transactions Sheet http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable Related Party Transactions (Details) - Schedule of related parties transactions Details http://geecenzymes.com/role/RelatedPartyTransactionsTables 29 false false R30.htm 029 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties balances Sheet http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable Related Party Transactions (Details) - Schedule of due to related parties balances Details http://geecenzymes.com/role/RelatedPartyTransactionsTables 30 false false R31.htm 030 - Disclosure - Income Taxes (Details) Sheet http://geecenzymes.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://geecenzymes.com/role/IncomeTaxes 31 false false R32.htm 031 - Disclosure - Commitments and Contingencies (Details) Sheet http://geecenzymes.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://geecenzymes.com/role/CommitmentsandContingencies 32 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentTransitionReport, dei:EntityRegistrantName, dei:SecurityExchangeName, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10q0323_genufood.htm 2744, 2745, 2773, 2774, 2775, 2776, 2816 f10q0323_genufood.htm f10q0323ex31-1_genu.htm f10q0323ex31-2_genu.htm f10q0323ex32-1_genu.htm f10q0323ex32-2_genu.htm gfoo-20230331.xsd gfoo-20230331_cal.xml gfoo-20230331_def.xml gfoo-20230331_lab.xml gfoo-20230331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0323_genufood.htm": { "axisCustom": 0, "axisStandard": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 304, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 99, "dts": { "calculationLink": { "local": [ "gfoo-20230331_cal.xml" ] }, "definitionLink": { "local": [ "gfoo-20230331_def.xml" ] }, "inline": { "local": [ "f10q0323_genufood.htm" ] }, "labelLink": { "local": [ "gfoo-20230331_lab.xml" ] }, "presentationLink": { "local": [ "gfoo-20230331_pre.xml" ] }, "schema": { "local": [ "gfoo-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 290, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 52, "http://geecenzymes.com/20230331": 13, "http://xbrl.sec.gov/dei/2023": 10, "total": 75 }, "keyCustom": 28, "keyStandard": 161, "memberCustom": 13, "memberStandard": 7, "nsprefix": "gfoo", "nsuri": "http://geecenzymes.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:TradingSymbol", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://geecenzymes.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:TradingSymbol", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Going Concern", "menuCat": "Notes", "order": "10", "role": "http://geecenzymes.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Equipment", "menuCat": "Notes", "order": "11", "role": "http://geecenzymes.com/role/Equipment", "shortName": "Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Investment", "menuCat": "Notes", "order": "12", "role": "http://geecenzymes.com/role/Investment", "shortName": "Investment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Stockholders\u2019 Equity (Deficit)", "menuCat": "Notes", "order": "13", "role": "http://geecenzymes.com/role/StockholdersEquityDeficit", "shortName": "Stockholders\u2019 Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "14", "role": "http://geecenzymes.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "15", "role": "http://geecenzymes.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://geecenzymes.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "17", "role": "http://geecenzymes.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "18", "role": "http://geecenzymes.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)", "menuCat": "Tables", "order": "19", "role": "http://geecenzymes.com/role/StockholdersEquityDeficitTables", "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Related Party Transactions (Tables)", "menuCat": "Tables", "order": "20", "role": "http://geecenzymes.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c53", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - General Organization and Business (Details)", "menuCat": "Details", "order": "21", "role": "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "shortName": "General Organization and Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c53", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c57", "decimals": "4", "first": true, "lang": null, "name": "gfoo:AverageExchangeRates", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "22", "role": "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c57", "decimals": "4", "first": true, "lang": null, "name": "gfoo:AverageExchangeRates", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Going Concern (Details)", "menuCat": "Details", "order": "23", "role": "http://geecenzymes.com/role/GoingConcernDetails", "shortName": "Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c59", "decimals": "0", "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Equipment (Details)", "menuCat": "Details", "order": "24", "role": "http://geecenzymes.com/role/EquipmentDetails", "shortName": "Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Investment (Details)", "menuCat": "Details", "order": "25", "role": "http://geecenzymes.com/role/InvestmentDetails", "shortName": "Investment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details)", "menuCat": "Details", "order": "26", "role": "http://geecenzymes.com/role/StockholdersEquityDeficitDetails", "shortName": "Stockholders\u2019 Equity (Deficit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToWrittenPutOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details) - Schedule of fair value the stock options black-scholes option pricing model", "menuCat": "Details", "order": "27", "role": "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable", "shortName": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of fair value the stock options black-scholes option pricing model", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details) - Schedule of stock options", "menuCat": "Details", "order": "28", "role": "http://geecenzymes.com/role/ScheduleofstockoptionsTable", "shortName": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of stock options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c71", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Related Party Transactions (Details) - Schedule of related parties transactions", "menuCat": "Details", "order": "29", "role": "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable", "shortName": "Related Party Transactions (Details) - Schedule of related parties transactions", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c71", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueOffBalanceSheetRisksTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "gfoo:DueToRelatedPartiesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties balances", "menuCat": "Details", "order": "30", "role": "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "shortName": "Related Party Transactions (Details) - Schedule of due to related parties balances", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueOffBalanceSheetRisksTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "gfoo:DueToRelatedPartiesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsNetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "31", "role": "http://geecenzymes.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsNetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "32", "role": "http://geecenzymes.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://geecenzymes.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consoildated Statements of Stockholders\u2019 Equity (Deficit) (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://geecenzymes.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consoildated Statements of Stockholders\u2019 Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c36", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://geecenzymes.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - General Organization and Business", "menuCat": "Notes", "order": "8", "role": "http://geecenzymes.com/role/GeneralOrganizationandBusiness", "shortName": "General Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_genufood.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 20, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "gfoo_AverageExchangeRates": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Average Exchange Rates", "terseLabel": "Average exchange rates" } } }, "localname": "AverageExchangeRates", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "gfoo_CommonStockIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of common stock issued.", "label": "Common Stock Issued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockIssued", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "gfoo_CommonStockIssuedinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares common stock issued.", "label": "Common Stock Issuedin Shares", "terseLabel": "Common stock issued (in Shares)" } } }, "localname": "CommonStockIssuedinShares", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "gfoo_DavidTangMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "David Tang Member", "terseLabel": "David Tang [Member]" } } }, "localname": "DavidTangMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable" ], "xbrltype": "domainItemType" }, "gfoo_DiscountOnCommonStock": { "auth_ref": [], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of discount on common stock.", "label": "Discount On Common Stock", "terseLabel": "Discount on common stock" } } }, "localname": "DiscountOnCommonStock", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "gfoo_DiscountOnCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discount On Common Stock Member", "terseLabel": "Discount on common stock" } } }, "localname": "DiscountOnCommonStockMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "gfoo_DiscountsOnCommonStockPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for discounts on common stock.", "label": "Discounts On Common Stock Policy Text Block", "terseLabel": "Discounts on Common Stock" } } }, "localname": "DiscountsOnCommonStockPolicyTextBlock", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "gfoo_DisposalOfSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of disposal of subsidiary.", "label": "Disposal Of Subsidiary", "terseLabel": "Disposal of subsidiary" } } }, "localname": "DisposalOfSubsidiary", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "gfoo_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://geecenzymes.com/20230331", "xbrltype": "stringItemType" }, "gfoo_DueToRelatedParties": { "auth_ref": [], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due To Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedParties", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "gfoo_DueToRelatedPartiesBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of due to related party balance.", "label": "Due To Related Parties Balance", "terseLabel": "Due to related party balance" } } }, "localname": "DueToRelatedPartiesBalance", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable" ], "xbrltype": "monetaryItemType" }, "gfoo_EmploymentVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employment Vesting Percentage", "terseLabel": "Employment vesting percentage" } } }, "localname": "EmploymentVestingPercentage", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "percentItemType" }, "gfoo_EquipmentDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equipment Details Line Items", "terseLabel": "Equipment [Abstract]" } } }, "localname": "EquipmentDetailsLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/EquipmentDetails" ], "xbrltype": "stringItemType" }, "gfoo_EquipmentDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equipment (Details) [Table]" } } }, "localname": "EquipmentDetailsTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/EquipmentDetails" ], "xbrltype": "stringItemType" }, "gfoo_EquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equipment [Abstract]" } } }, "localname": "EquipmentLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/Equipment" ], "xbrltype": "stringItemType" }, "gfoo_EquipmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equipment [Table]" } } }, "localname": "EquipmentTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/Equipment" ], "xbrltype": "stringItemType" }, "gfoo_ForeignCurrencyTransactionAdjustments": { "auth_ref": [], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Foreign currency transaction adjustments.", "label": "Foreign Currency Transaction Adjustments", "negatedLabel": "Foreign currency transaction adjustments" } } }, "localname": "ForeignCurrencyTransactionAdjustments", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "gfoo_GeneralOrganizationandBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Organization and Business (Details) [Line Items]" } } }, "localname": "GeneralOrganizationandBusinessDetailsLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "gfoo_GeneralOrganizationandBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Organization and Business (Details) [Table]" } } }, "localname": "GeneralOrganizationandBusinessDetailsTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "gfoo_GeneralOrganizationandBusinessLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Organization and Business [Abstract]" } } }, "localname": "GeneralOrganizationandBusinessLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusiness" ], "xbrltype": "stringItemType" }, "gfoo_GeneralOrganizationandBusinessTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Organization and Business [Table]" } } }, "localname": "GeneralOrganizationandBusinessTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusiness" ], "xbrltype": "stringItemType" }, "gfoo_GoingConcernDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern (Details) [Line Items]" } } }, "localname": "GoingConcernDetailsLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "xbrltype": "stringItemType" }, "gfoo_GoingConcernDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern (Details) [Table]" } } }, "localname": "GoingConcernDetailsTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "xbrltype": "stringItemType" }, "gfoo_GoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "gfoo_GoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Table]" } } }, "localname": "GoingConcernTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "gfoo_HsinTaDarrenSuMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hsin Ta Darren Su Member", "terseLabel": "Hsin-Ta (Darren) Su [Member]" } } }, "localname": "HsinTaDarrenSuMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_HuiChuanSandraLinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hui Chuan Sandra Lin Member", "terseLabel": "Hui-Chuan (Sandra) Lin [Member]" } } }, "localname": "HuiChuanSandraLinMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_HukuiAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hukui Agreement Member", "terseLabel": "Hukui Agreement [Member]" } } }, "localname": "HukuiAgreementMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "gfoo_HukuiBiotechnologyCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hukui Biotechnology Corporation Member", "terseLabel": "Hukui Biotechnology Corporation [Member]" } } }, "localname": "HukuiBiotechnologyCorporationMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "xbrltype": "domainItemType" }, "gfoo_IncomeTaxesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes Details Line Items", "terseLabel": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesDetailsLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "gfoo_IncomeTaxesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "localname": "IncomeTaxesDetailsTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "gfoo_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "gfoo_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "gfoo_IncreaseDecreaseIncommitmentsAndContingencies": { "auth_ref": [], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commitment and contingencies.", "label": "Increase Decrease Incommitments And Contingencies", "terseLabel": "Commitment and contingencies" } } }, "localname": "IncreaseDecreaseIncommitmentsAndContingencies", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gfoo_InvestmentDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment (Details) [Line Items]" } } }, "localname": "InvestmentDetailsLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "gfoo_InvestmentDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment (Details) [Table]" } } }, "localname": "InvestmentDetailsTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "gfoo_InvestmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment [Abstract]" } } }, "localname": "InvestmentLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/Investment" ], "xbrltype": "stringItemType" }, "gfoo_InvestmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment [Table]" } } }, "localname": "InvestmentTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/Investment" ], "xbrltype": "stringItemType" }, "gfoo_IssuanceOfCommonStockForDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for debt conversion.", "label": "Issuance Of Common Stock For Debt Conversion", "terseLabel": "Issuance of common stock for debt conversion" } } }, "localname": "IssuanceOfCommonStockForDebtConversion", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gfoo_JiaTianJefferyLinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jia Tian Jeffery Lin Member", "terseLabel": "Jia Tian (Jeffery) Lin [Member]" } } }, "localname": "JiaTianJefferyLinMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_JuiPinJohnLinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jui Pin John Lin Member", "terseLabel": "Jui Pin (John) Lin [Member]" } } }, "localname": "JuiPinJohnLinMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_KuangMingJamesTsaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kuang Ming James Tsai Member", "terseLabel": "Kuang Ming (James) Tsai [Member]" } } }, "localname": "KuangMingJamesTsaiMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_NanYaoJakeChanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nan Yao Jake Chan Member", "terseLabel": "Nan-Yao (Jake) Chan [Member]" } } }, "localname": "NanYaoJakeChanMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_NumberOfUnderlyingSharesVestedAndExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Underlying Shares Vested And Expected To Vest", "terseLabel": "Number of Underlying Shares Vested and expected to vest" } } }, "localname": "NumberOfUnderlyingSharesVestedAndExpectedToVest", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "sharesItemType" }, "gfoo_PenaltyReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.", "label": "Penalty Received", "terseLabel": "Penalty received" } } }, "localname": "PenaltyReceived", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "gfoo_PercentageOfEquityInvestment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage Of Equity Investment", "terseLabel": "Percentage of equity investment" } } }, "localname": "PercentageOfEquityInvestment", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "percentItemType" }, "gfoo_PurchaseOfAdditionalShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase of additional shares.", "label": "Purchase Of Additional Shares", "terseLabel": "Purchase of additional shares (in Shares)" } } }, "localname": "PurchaseOfAdditionalShares", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "sharesItemType" }, "gfoo_PurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchase price.", "label": "Purchase Price", "terseLabel": "Purchase price" } } }, "localname": "PurchasePrice", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "gfoo_SaleOfSharesDuringTheTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Shares During The Transaction", "terseLabel": "Selling shares", "verboseLabel": "Selling aggregate shares (in Shares)" } } }, "localname": "SaleOfSharesDuringTheTransaction", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "sharesItemType" }, "gfoo_ScheduleOfDueToRelatedPartiesBalancesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Due To Related Parties Balances Abstract" } } }, "localname": "ScheduleOfDueToRelatedPartiesBalancesAbstract", "nsuri": "http://geecenzymes.com/20230331", "xbrltype": "stringItemType" }, "gfoo_ScheduleOfFairValueTheStockOptionsBlackScholesOptionPricingModelAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value The Stock Options Black Scholes Option Pricing Model Abstract" } } }, "localname": "ScheduleOfFairValueTheStockOptionsBlackScholesOptionPricingModelAbstract", "nsuri": "http://geecenzymes.com/20230331", "xbrltype": "stringItemType" }, "gfoo_ScheduleOfRelatedPartiesTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Related Parties Transactions Abstract" } } }, "localname": "ScheduleOfRelatedPartiesTransactionsAbstract", "nsuri": "http://geecenzymes.com/20230331", "xbrltype": "stringItemType" }, "gfoo_ScheduleOfStockOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Stock Options Abstract" } } }, "localname": "ScheduleOfStockOptionsAbstract", "nsuri": "http://geecenzymes.com/20230331", "xbrltype": "stringItemType" }, "gfoo_ShaoChengWillWangMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shao Cheng Will Wang Member", "terseLabel": "Shao-Cheng (Will) Wang [Member]" } } }, "localname": "ShaoChengWillWangMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueForfeitedOrExpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Forfeited Or Expired", "terseLabel": "Aggregate Intrinsic Value, Forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueForfeitedOrExpired", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "monetaryItemType" }, "gfoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Granted", "terseLabel": "Aggregate Intrinsic Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "monetaryItemType" }, "gfoo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted Average Remaining Contractual Life, Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "durationItemType" }, "gfoo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingForfeitedorexpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life forfeited or expired.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Forfeitedorexpired", "terseLabel": "Weighted Average Remaining Contractual Life, Forfeited or expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingForfeitedorexpired", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "durationItemType" }, "gfoo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted Average Remaining Contractual Life (years), Ending Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "durationItemType" }, "gfoo_StockIssuedDuringValueIssuanceOfCommonStockForDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of stock issued during value issuance of common stock for debt conversion.", "label": "Stock Issued During Value Issuance Of Common Stock For Debt Conversion", "terseLabel": "Issuance of common stock for debt conversion" } } }, "localname": "StockIssuedDuringValueIssuanceOfCommonStockForDebtConversion", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "gfoo_StockIssuedDuringValueIssuanceOfCommonStockForDebtConversions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of stock issued during value issuance of common stock for debt conversion.", "label": "Stock Issued During Value Issuance Of Common Stock For Debt Conversions", "terseLabel": "Issuance of common stock for debt conversion (in Shares)" } } }, "localname": "StockIssuedDuringValueIssuanceOfCommonStockForDebtConversions", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "gfoo_StockOptionCompensationExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock Option Compensation Expenses", "terseLabel": "Stock option compensation expenses" } } }, "localname": "StockOptionCompensationExpenses", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "gfoo_StockholdersEquityDeficitDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) (Details) [Line Items]" } } }, "localname": "StockholdersEquityDeficitDetailsLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "gfoo_StockholdersEquityDeficitDetailsScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of The Fair Value of the Stock Options Listed above was Determined using the Black Scholes [Abstract]" } } }, "localname": "StockholdersEquityDeficitDetailsScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable" ], "xbrltype": "stringItemType" }, "gfoo_StockholdersEquityDeficitDetailsScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of fair value the stock options black-scholes option pricing model [Table]" } } }, "localname": "StockholdersEquityDeficitDetailsScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable" ], "xbrltype": "stringItemType" }, "gfoo_StockholdersEquityDeficitDetailsScheduleofstockoptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of the Option Activity [Abstract]" } } }, "localname": "StockholdersEquityDeficitDetailsScheduleofstockoptionsLineItems", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "stringItemType" }, "gfoo_StockholdersEquityDeficitDetailsScheduleofstockoptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of stock options [Table]" } } }, "localname": "StockholdersEquityDeficitDetailsScheduleofstockoptionsTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "stringItemType" }, "gfoo_StockholdersEquityDeficitDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) (Details) [Table]" } } }, "localname": "StockholdersEquityDeficitDetailsTable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "gfoo_WeightedAverageExercisePriceVestedAndExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Vested And Expected To Vest", "terseLabel": "Weighted average exercise price Vested and expected to vest" } } }, "localname": "WeightedAverageExercisePriceVestedAndExpectedToVest", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "perShareItemType" }, "gfoo_WeightedAverageRemainingContractualLifeExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life, exercisable.", "label": "Weighted Average Remaining Contractual Life Exercisable", "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable" } } }, "localname": "WeightedAverageRemainingContractualLifeExercisable", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "durationItemType" }, "gfoo_WenPiaoJackLaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wen Piao Jack Lai Member", "terseLabel": "Wen-Piao (Jack) Lai [Member]" } } }, "localname": "WenPiaoJackLaiMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "gfoo_YiLungOliverLinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Yi Lung Oliver Lin Member", "terseLabel": "Yi Lung (Oliver) Lin [Member]" } } }, "localname": "YiLungOliverLinMember", "nsuri": "http://geecenzymes.com/20230331", "presentation": [ "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r138", "r205", "r449", "r468" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable", "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r138", "r205", "r449", "r450", "r468" ], "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable", "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r471", "r486" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable", "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r18", "r53", "r103", "r309", "r322", "r323" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r2", "r7", "r18", "r253", "r256", "r279", "r318", "r319", "r457", "r458", "r459", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r48", "r430", "r493" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r223", "r224", "r225", "r337", "r465", "r466", "r467", "r484", "r494" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in-Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r75", "r98", "r123", "r152", "r164", "r168", "r174", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r248", "r250", "r262", "r305", "r370", "r430", "r441", "r478", "r479", "r488" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r94", "r104", "r123", "r174", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r248", "r250", "r262", "r430", "r478", "r479", "r488" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnitsNetAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net amount applicable to investors of capital units or shares.", "label": "Capital Units, Net Amount", "terseLabel": "Penalty amount" } } }, "localname": "CapitalUnitsNetAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r21", "r96", "r422" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r21", "r60", "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r60" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r91", "r100", "r101", "r102", "r123", "r141", "r143", "r145", "r147", "r150", "r151", "r174", "r179", "r181", "r182", "r183", "r186", "r187", "r189", "r190", "r192", "r195", "r201", "r262", "r328", "r329", "r330", "r331", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r358", "r379", "r402", "r415", "r416", "r417", "r418", "r419", "r448", "r463", "r469" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r15", "r41", "r307", "r357" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitment and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r67", "r177", "r178", "r421", "r474" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r465", "r466", "r484", "r492", "r494" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r47", "r358" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r47", "r358", "r376", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r47", "r308", "r430" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r19", "r106", "r108", "r114", "r301", "r315" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r42", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r33", "r424" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principle of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r349", "r350", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r389", "r390", "r391", "r392", "r395", "r396", "r397", "r398", "r411", "r412", "r413", "r414", "r431", "r433" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r34", "r35", "r36", "r37", "r349", "r350", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r389", "r390", "r391", "r392", "r395", "r396", "r397", "r398", "r411", "r412", "r413", "r414", "r423", "r431", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r115", "r130", "r131", "r132", "r133", "r134", "r139", "r141", "r145", "r146", "r147", "r148", "r260", "r261", "r302", "r316", "r427" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "BASIC & DILUTED LOSS PER SHARE (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r115", "r130", "r131", "r132", "r133", "r134", "r141", "r145", "r146", "r147", "r148", "r260", "r261", "r302", "r316", "r427" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "DILUTED LOSS PER SHARE" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r24", "r25" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Tax benefit" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r92", "r110", "r111", "r112", "r125", "r126", "r127", "r129", "r135", "r137", "r149", "r175", "r176", "r203", "r223", "r224", "r225", "r241", "r242", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r268", "r269", "r270", "r271", "r272", "r273", "r279", "r318", "r319", "r320", "r337", "r402" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Aggregate investment" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "auth_ref": [ "r173" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.", "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Loss of market value" } } }, "localname": "EquityMethodInvestmentQuotedMarketValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]" } } }, "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r264", "r265", "r266", "r267", "r399" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "terseLabel": "Foreign currency income (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": { "auth_ref": [ "r460", "r461", "r462", "r490" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.", "label": "Gain (Loss) on Disposition of Stock in Subsidiary", "negatedLabel": "Loss on disposal of subsidiary", "terseLabel": "Loss on disposal of subsidiary" } } }, "localname": "GainOrLossOnSaleOfStockInSubsidiary", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow", "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56", "r381" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r54", "r77", "r152", "r163", "r167", "r169", "r303", "r313", "r428" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r124", "r230", "r235", "r236", "r239", "r243", "r245", "r246", "r247", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Total amount of penalty and interest" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Expense", "terseLabel": "Forgiveness of penalty and interest" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r81", "r90", "r136", "r137", "r155", "r233", "r244", "r317" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r109", "r231", "r232", "r236", "r237", "r238", "r240", "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r5" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r5" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r5" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepayment" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToWrittenPutOptions": { "auth_ref": [ "r142", "r147", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of outstanding written put options using the reverse treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Written Put Options", "terseLabel": "Options to purchase shares" } } }, "localname": "IncrementalCommonSharesAttributableToWrittenPutOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r79" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income (expense)" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r116", "r118", "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentSoldNotYetPurchasedBalanceShares": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Number of securities sold short (the short position) as of the end of the period.", "label": "Security Sold Short, Shares", "terseLabel": "Company sold shares (in Shares)" } } }, "localname": "InvestmentSoldNotYetPurchasedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r451", "r452", "r472" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "INVESTMENT" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/Investment" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r52", "r76", "r311", "r430", "r464", "r473", "r485" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r95", "r123", "r174", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r249", "r250", "r251", "r262", "r430", "r478", "r488", "r489" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r475", "r476", "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Penalty imposed" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossOnSaleOfInvestments": { "auth_ref": [ "r460", "r461", "r462", "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.", "label": "Loss on Sale of Investments", "terseLabel": "Loss on sale" } } }, "localname": "LossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r61", "r62" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r55", "r62", "r78", "r93", "r105", "r107", "r112", "r123", "r128", "r130", "r131", "r132", "r133", "r136", "r137", "r144", "r152", "r163", "r167", "r169", "r174", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r261", "r262", "r314", "r378", "r400", "r401", "r428", "r439", "r478" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow", "http://geecenzymes.com/role/ConsolidatedIncomeStatement", "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r152", "r163", "r167", "r169", "r428" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r274", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionContractIndexedToEquitySettlementShareFairValuePerShare": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Fair value per share that would be issued upon settlement of option contract indexed to equity.", "label": "Option Contract Indexed to Equity, Settlement, Share, Fair Value Per Share", "terseLabel": "Options per share" } } }, "localname": "OptionContractIndexedToEquitySettlementShareFairValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r44", "r73", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "GENERAL ORGANIZATION AND BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]", "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Total investment" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other non-operating income (expenses), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingPolicyPercentageOfPremiumIncome": { "auth_ref": [ "r43", "r306" ], "lang": { "en-us": { "role": { "documentation": "Percentage of participating insurance to premium income.", "label": "Participating Insurance, Percentage of Premium Income", "terseLabel": "Income taxes return, percentage" } } }, "localname": "ParticipatingPolicyPercentageOfPremiumIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r46", "r189" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Purchase shares of stock (in Shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r456" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepayment" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r4" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [ "r20" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Proceeds from Sale of Equity Method Investments", "terseLabel": "Proceeds from sale of Hukui investment" } } }, "localname": "ProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r65", "r85", "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/Equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r66", "r97", "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/EquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r304", "r312", "r430" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesRequestedReturnOnEquityPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of public utility's requested return on equity.", "label": "Public Utilities, Requested Return on Equity, Percentage", "terseLabel": "Information return percentage" } } }, "localname": "PublicUtilitiesRequestedReturnOnEquityPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r204", "r283", "r284", "r352", "r353", "r354", "r355", "r356", "r375", "r377", "r409" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r283", "r284", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "auth_ref": [ "r80", "r99", "r276", "r277", "r278", "r282" ], "lang": { "en-us": { "role": { "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.", "label": "Related Party Transaction, Description of Transaction", "terseLabel": "Relationship with the Company" } } }, "localname": "RelatedPartyTransactionDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r382", "r383", "r386" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r204", "r283", "r284", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r352", "r353", "r354", "r355", "r356", "r375", "r377", "r409", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r280", "r281", "r282", "r284", "r285", "r334", "r335", "r336", "r384", "r385", "r386", "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r49", "r69", "r310", "r321", "r323", "r332", "r359", "r430" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r92", "r125", "r126", "r127", "r129", "r135", "r137", "r175", "r176", "r223", "r224", "r225", "r241", "r242", "r252", "r254", "r255", "r257", "r259", "r318", "r320", "r337", "r494" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r113", "r123", "r153", "r154", "r162", "r165", "r166", "r170", "r171", "r172", "r174", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r262", "r303", "r478" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "REVENUE" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Purchasing share value" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Purchasing shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "auth_ref": [ "r38", "r74" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.", "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]" } } }, "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofduetorelatedpartiesbalancesTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTextBlock": { "auth_ref": [ "r38", "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined) which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.", "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]", "terseLabel": "Schedule of due to related parties balances" } } }, "localname": "ScheduleOfFairValueOffBalanceSheetRisksTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r39", "r40", "r382", "r383", "r386" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofrelatedpartiestransactionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related parties transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r9", "r10", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of fair value the stock options black-scholes option pricing model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r171", "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Business Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r454", "r455", "r480" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock [Member]", "verboseLabel": "Series C Preferred Shares [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Aggregate Intrinsic Value Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "terseLabel": "Number of Underlying Shares, Forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Underlying Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Ending Outstanding", "periodStartLabel": "Aggregate Intrinsic Value, Beginning Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Underlying Shares, Ending Outstanding", "periodStartLabel": "Number of Underlying Shares, Beginning Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Ending Outstanding", "periodStartLabel": "Weighted average exercise price, Beginning Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of Underlying Shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r206", "r207", "r216", "r217", "r218", "r219", "r222", "r226", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleoffairvaluethestockoptionsblackscholesoptionpricingmodelTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Beginning Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life (years) Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Stock option period" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current", "terseLabel": "Cash price", "verboseLabel": "Selling shares value" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r63", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r91", "r100", "r101", "r102", "r123", "r141", "r143", "r145", "r147", "r150", "r151", "r174", "r179", "r181", "r182", "r183", "r186", "r187", "r189", "r190", "r192", "r195", "r201", "r262", "r328", "r329", "r330", "r331", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r358", "r379", "r402", "r415", "r416", "r417", "r418", "r419", "r448", "r463", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r16", "r92", "r110", "r111", "r112", "r125", "r126", "r127", "r129", "r135", "r137", "r149", "r175", "r176", "r203", "r223", "r224", "r225", "r241", "r242", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r268", "r269", "r270", "r271", "r272", "r273", "r279", "r318", "r319", "r320", "r337", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r125", "r126", "r127", "r149", "r288", "r326", "r348", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r381", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r402", "r434" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r125", "r126", "r127", "r149", "r288", "r326", "r348", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r381", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r402", "r434" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r46", "r47", "r69", "r328", "r402", "r416" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Purchase aggregate shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r46", "r47", "r69", "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Number of Underlying Shares, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ScheduleofstockoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r8", "r46", "r47", "r69", "r337", "r402", "r416", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r32", "r46", "r47", "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionExercisePriceIncrease": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.", "label": "Stock Option, Exercise Price, Increase", "terseLabel": "Stock price" } } }, "localname": "StockOptionExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option [Member]", "verboseLabel": "Stock Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r47", "r50", "r51", "r64", "r360", "r376", "r403", "r404", "r430", "r441", "r464", "r473", "r485", "r494" ], "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r68", "r122", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r203", "r258", "r405", "r407", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r26", "r27", "r28", "r82", "r83", "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r140", "r147" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "WEIGHTED AVERAGE NUMBER OF COMMON STOCKS-DILUTED" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r139", "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "WEIGHTED AVERAGE NUMBER OF ORGINARY SHARES-BASIC & DILUTED (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(14)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-35", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "36", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-36", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479756/944-50-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r444": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r445": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r446": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r447": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org//321/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org//325/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(g))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 51 0001213900-23-045798-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-045798-xbrl.zip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ɯ?%1R^G^-PZ7O)A,O:?+77B6DZ5KMR@NC#_(8 VX"#2\;UI8+ MRRY"V6#TE@S+KR!5,+I]#-)>^%#'P+<1/M1";#59D-7\TN)Z@TM$.3W;.4%] M*ZE:'BIPM5UT(CE+:SZ@1VM"K67HV;_UYR$$G^)_8J5[X&L>7]UN^8+%B+.M MUN,Q;?X7F;],RK1+MMY>Y,;/_CEQ+^5;[CW/YW,,OI)TS/S 5J&N1=LBZ=D^ MJFDUV3ZI93^N\'2A8FV2J167SCO7'/"B]=:Z\W=Q4)FB>(T+0:5%\5JU=M%Z M[<631EXZZ4LZ]]DJ0=Y08;HDU7[<3I%4!VDHH6X:M7FT5'27,_=6:3JZ[8A# M3;G+GBK=X63GXGWF;#!])LN4Y H$;&]A6TFO"!=4_E+S14*'SV"?3*/N;C,5 MWZ,R]R2T)-TA16T*:-IY2@.P#8I2PQ.KK\*I*7A8/ .0A!(S>.EQ[]M7!V@=.E07'AI:59GH:-:F[0>27C(-/5->I MW>=J:T7)9[9#.6D%$*9U"#3(*W*=3[U<77+S TXB0!NG^1R!$FDKBWFU"1Z4 M3"I .,@=R+Z2O$42NP2._8&?H;5 CJ;&O=44#_GEX/ ;]:3U?@2U):'L.ZO) M:"5-2*Z\'N ]S%6A0FWR,^Q! [T:"/312/; M^S_0WRQ7C6C(EAK):=>O58ULWIQ4*-O>&LN*._^HJ0*RPURC,M5\S[1[Q"4C M[%$QUR2PDI).0YQTXBH[BX./%!/"F>]5-Q8E']KOJ=,D^&T3G0.@89(P-MK( ME&K,P23!LTU 1FEN@U%#RI;7KS.TTF+F;\BEC_?-C=!AWTU MVBWN>LG0,65$BL1M[DZT="%WM4L1Z('N6,2))?XKXB.>/XBY:H97A\,8NS56 M048WLW4XH,DC[G(ZUB](U0ON\'2[ JQ!GF(4*\-.-_%/&TTK&'#IX2D*2#"9 M9VMUN-NS4I#8BA7;G?J5JA3;@6[[J89!]:U.[Z6A2P&[)8$]V-.GH3B)WBSJZ1D M^9D<59NK1@RLT[5NZPZQO3AH76/6F4K1')1\Y5 $ZWRM(^D+1%C\'/ U1F+K M*':6"8=FI2U/U^9V74W>"EA"O;BL)?+*Q\"#_&O@A@U>GX\A.8$6:(,]_*R5 M@L +H;^W>.VSW5P-.P4YFD.2OB2*8-T@="1]CACEK(G.=/'S>V9EW$1M..Z^ M$3?]IZ7UG;Q( L=O)$UHIG=%K4@K3DWE1AJ",4IBLA77:TO[I_*G+R?K;?KE M,MXKD W:P6T^]7@8#CFJH5OFOBPTT5X=\!JUB57DAE0,J0:JE2$%M\' M^)*9"_,I_]%)KIAV$50IDQ]6XE(=W50A@!)EU@NBXWH:[1/2;Z,DVEEB-XI? M!MYY^>V+,J,OB+DQX<35!V*'GJAS$$2KY'Q? M-IEL0)&=S+8=_:9S]5)D:&#U^@ 2 'XSR'8A_VX)T'6@WTP]_UXY:K$R;XR2 MY&U[:?-XM,8[/W,Q56:F2'[92R&(,^WAW M9V'X=I[^?,[G^2#F&2YQ(-8,?-N@(6[KNEWW&OB1CQ1X]$JEJ+ M?YQ91OE_[9?0ZG%MK9&=>BBA,#709H2L(Z_M6!]HL,8.F1/LGODK1"B$S"K' MMG-@U*B?.Z2K0ZU^%ZHU^]F+ON]_._'Q\?_<_'Z]^__]__^9>S MCAX_T>]?NU]_?%A\VM /9]&7MS^RUS_^^O+/#]--X/WXX'Q][KT+3\([_.[K MCZ_N'U\X5^'SSQ<7+^]^/7EX/!U_>O[@WK%/[)US?K9&F]':^Q/??YSX'[]' M;T>OOSCHT[OEE[?WSS\__^W/&W<37_,WJ_^=U_ M/G/_FOWZSD$OQ@_>>/D0OGTW^GB_\$X_G?UZ'])?-I/PY&H/Z MZ_KSS3]_>$#?_Q).9]>G=Y_'P;^^?EY\\M;OKG]]=;+$[T?K7SY0]'C]PY7_ M\(]WEXQY/RSIQ?/;DPBM?PO/1_^8_77Z^L^3S\]O/G_^938;WRTO)N]/'Z?X M>G'&_ODBC-#TGR<>>?UB-HWN'\^_.'\NOD[^]=OHS9O_/1K?W1X?:V_!2[,R M(\;$NW;"_DXWY7G W2*;R?V)3<,%PSA]]D:\B]?)L29+4* &F\[K M=U_4-GI<0GWWVQ4<6ZF L*_?IO4 \*I*?Y3]C(A'J:D[%%7/\?L4HIA0 K!+ M/'8RW%F@=WEKO:QU[E!6+Q==.H3ZH9"\SA6G#YL5+8ZO6I2@1\M4EK>A^M9ICU)=BMY,]&?1O0T@P2L%8+3C^'ML;EAK;U?:6R]H_8BL3*<[S@XW3O86 MBZ4T>;HICF0CY(GTX,C^ [DIE@L.G6*)>@%;[ M\#3.*%":4I]"84#.^WY* :? D.*VT6RH;0 4SP\?3DPR^*W*9'?,T\#3#IV+ MT$J_H[9+23[ VA\Z7K4(,+:S M$6=SDD%&;VIK6\S@&U/WKN4/U]'+4O*I8.-3/T1>KS.F4BQ_8WIM7,+6^YJU MG>:%S^:8A!&7M7B._G%-DD[HNVGW3(N;^?W[I*?:BQ:N"YN5^#HSPR%&V*KL M_WTT&USPJ:)W^Y*#X>3=%@7L^@P+ZU9)>77*U3=PZ&5!E*G.MC\+4XPM8'-_ MNZE-V+FJEIIDXELX&# JI%3_6A]96:]D20HM_WC>LUBVM$9VV&[2J/!2A=0X MFTKJ5LZI:SABA2F?[+.F-D:H3^JK).=4J36.Q$J4NMOX5+U 4O*VFP6^AI_Y MLB+-5'W;G]'UJMJUSQ[X*66K(\U4437.V4K]K)*^)C',9/Z!_DG*2JF,./K94!C$MQ>^ZXW'=DM]&XCKC#GR7JP5E*G=+ M+R6W78NTF\:U9A 4U2+4?IE-0YYN9"D>0*=#I9:< :;:?DDNJ M?+-+! M,A6ZI4?(%"W.L"5/UY//F^MHJ06@#$Q:ON6V"RY"DL+JR08-$Z M,/_&F>*KJZ4OI_%QFY_<:^R.*3%@^ROGPQ!^JJ63ZN M[3?^6AEUVNJQ C(0\2G)[Q.YBNABXA$>FG&;N<;%;$.%!RW_TL:RWZB# O6* MB5IZ8/-=1&X(?>1A'SBF]M M.2(YZ*LF#-7K3&TO36\(\M\AY_X*$07H2S^TM!^6@KU\IJ#=[%4JQ?SQ$M/% M1^)Y'_E^10'XJF][K?.5$X9J4*6"_J^18(#0Q3O$=TC30$GO*S_NKZ^OGB]4 M%R6UZAU$/PD[O,?C)5+Q]J4?]MGEE,\4K"60$NJ_!(1.T1GBQ.A=I(!ZZ8=] M1KU\IE"M-+9Q&>^OD$WNEV9,ULL\R(+0[OB^^N3^;S+8&[)<:A>!&T[$TFP#RS!&G= MA'KMT&@H=7E&6D:W8#*93ZEHR6A!WMP[ MR4"WE]M'$BYC'14QSY*LI_XY#<6!+M0K4:H4^[OSUL(O_Z#44V*C16*CXTSV MW_[DH-O&1T\G!]!9[*<<]E!RV$_G-D"9ZZO4]5,2%3B)K8+^&>), M3M7\^^$W?=;TPOS@VJ0/;O<)DLR!R%XK*6AETD1.5ZL_MWG< )!/B[6[!ARH MW'*'F>6WF&*&O E;($J^QJ-R'WD:\=4*!\&VEEPUJ9Q"/G(7W+5FSLVZ):Q519S= M%Z3NWQ[9OI@^]E 03.;QW0[9;*[2 R]5="S%$^K6EG^RI1*VSFO#=SQAQE5Q M?)/2C'DJ"_3:"[.&DN5@J4F=8QU-WDZ;+G&EY*LRV$V#V%G3]"78C(J-ZPFYN[[! M733[$SOAU+_FDQ)_O;G%+E[%=5-W. R]>!F/6VF.5B+<'D6 ABU;$OYE,$J;G44)XV@ M)^LX<**+.[R(6Z\!ZTTUG4%(3@(NL-!2TP60Q[R7E[@=/T:/0+]%6 MA]"(<[IEF0?)P*)5(&PW[Z(F:A4\(:N1.CO9\).N2PYF-+< Z2A?=KT7^S". MKYN(EKHW&;XG\PO" P*'(&^7!3.U5,'PI.I82V!5. ZI^AB "\63CKH!;-6&RMK%60 MA')D.A(?HV YNHT WSUYBOYS>>R!]3=S>LH:US,SV-Q>T0"_EMGB2AE !^[JZ0I1;ZX0 M:3B_!\QFOMU#GF874A?-Z]<'M[L>).!/[JHD=>_):Z9)JOH]_A+_$[SWER)J MR\,T;[KRZX$<@H />NA?(C#VEN7N7LV(+FO^CWHG4P.ZA++%H(3^8CUXU/4Y%75F30 '?)Y_W5][HYPS5STRR7 M%N_:[ZP5AN^OE*H1L=/ZC4>2C@!HP?4F6?'V3,G92MT /?=4M7,'>\_D MZ>JTBE"DKTEKM(^KVL$_797NHR8 7XM^W5Y?=+3ER@^""4VTVMP*6$6EWPZX M$:-T[VREFTGY!O"WR ^Q>XW8/0Y-O%HO2]7*H1[$#KH$P%3,(#F2SJZZB^WD MTOI[O"1X?OZ(G4CT"9C,N7YA)G\2W? J4=WH?2QA:A!#(V"6*[+/ M,",/*&GXP!>"2,1FHO>U >=92\J6D6D[S'K@+/7@W#,E.G:(97W*OS+B*&M) MV7:9,EI=+LPRW%J4&^9BK\FZZMXU3 2?&]]NI8ZJ $KP@2O1Z;]34=B.6"K? M&?NKE4\SAZ>CB&_H&?D*?LQ<1ZF?075M^J,6.,!2G99"Y<'+A,7U=6Z0O?87&"''E;AA.-#$-&9E$HO-+4_\A(&&)Z$X6) M/X:_D:_%A)78OY5.Z*)MLP%PPD0:!%U2%S]B=^HG<]\?L,0SV3V=8\A7M..E MC^M^K;JTA-Y.$=,^WIN+!B0Q]T*Y^4S$G=7SU=KS-WS\:Q1RO.*F"+L_&%$: M(>]W'(1)+>OV%!Y\GP+'V1!7)E#)6"GC2E@5NM^@*U5-#&J^'U! 60L#5&F7 M=B7$3+2?X"NZ V]_(Q;'[8+X M$9/%D@=3VS;"MUALRE.%Y9Z2:ZHX[W]IHJ2B![,:HL_I"W9PU70M2UD7+R3$\=FL;Z?'EJ!":FK,3!(CZ*!,]@#L\J% M!6DHO^?F_%'\*%EXWC3&8+8VC6#H%^655J1WU\-FVQL]_XB%9DHF&6K?JL10 MD4\=)8UV,8<(J+2L*?]6HRR@.%1!#Q59N2*Y#F?6#E D]"*YZ%LA!X :#0MU MA;5*53[?XM&(I8X68[0F(?(^4!(&[W&8E!]#I\]+:?1#5O7Y\7)P+)U_W&"* MO'"3OI8GY2H.O[%V>U4*]\(,;;_3$C^*[I UVCU$LLE>O+EA>$6B53([8*-1 M(FVIH%K)F-2PM'HY>3>S\T>T(C0&,]%-\0X-=2\I)X*#C M)'UE2 $?!#2J R/'8?"WUE6I?U,ZL(,4+''?[49+G)N2Y!H0HF[R"M4"T\+K M@;K%#]NQ1X=CF]Z+J='63T_M'FR[$MFR&[0Q70V7Q9 M6]R0VT]EFVC&X[L/(?&(\.VW M^*^(^W7LWN(P8G1"DURG*G+$$V/ENX3^<\,\3.^$_[,VC M=E"-4+EBO(ID9GM&;6]$#,.VE)61D;):N91GL/4U*,$T%N\( )' M&KY'M1F59OTI'=!*GD363%*HRZ&PE'04#$T9RMQ%59GL4='Q#/&@]D(PNO*H'\S&T4&@LNMCU9+G@\AKQ/&+%SZIZAL)TL M*@>U%9&JRJ8:%3NEO7L'6KC",HG"($14&#/ RE([_%"D)X,47!).58XC/@U7 M3.7"0^U$EA]I&.O.P>S!VB!J6A,658I>7.#_*]Y &-#!B/T*@IM,YA .N Z( MVA)*//$M7OM,I _$9:ZHW1ZL=N!A6%$]-E;Z).[9NB >9F.^6BY\!F%2^?&& MM0@=8 %6!JD=9R>UFA!!7OF( _%W%7 UT!J26@?=%[PW\"DFP[''(:7JT0$ MK EA6RDEZ@,MI^RH@\CMU( "UTA0.X2X6R'/.XT"SGWMNZ:RZU%^O&&M1P=8 MI-)I?UZB*YSS%68+'KN\9?Z7<"DJTQ&%"!K*QQU"7J@6EU1@[?,/FK:TQ)X' M)Z7<<,-8E,IP2*5B(9N0LOY;A!@?R]LDNP&0U>APS&$(J!*15$H ;R[H;XS> M1PT=IU1V1=O!!A)S%T%()=(ZOZ G#U&YQ[AN)#=BP_@)H8B&;#/V78ACNOKQ M!Q'920&5BA'BXJ>F*$>NRT$,MO\GIO,"0(!EHPY(;*6@I,("R$' ":NN88"^ ML%X.6UC[._,OK"0D8M\\ M83?,?R"T]LU'15$=#CQ >16P2876\1W% F,W?A B[S-9 X4=I<,.*D8L!R:5 M5_0&&D(N(C_S5 #=)Q^N?)%77/H48O]4&&P@ME$$(15(Z[R# MJCSNL!,QKALO7LZF)&Q9O%L8;"#R*(*0RJ/3UE]95LX?G:7HT]2ZSK1TP$%$ MT^50I)*Q6,DP18^7+I\$F1,GG@)8*JAJY&$=353BD\JNZ[Y2V?P''T@\,?& MSU"(FM\-E,\0E0X\I.BZ"IM4:A9K'>*70>)W=P&3XH5!AV)EU:BDHH+(,E3> MF_KY1' C&A&*__H_4$L! A0#% @ T(/"5J;\I-/KG@ -4,& !4 M ( ! &8Q,'$P,S(S7V=E;G5F;V]D+FAT;5!+ 0(4 Q0 ( M -"#PE9RI?*ZJP< ,LH 7 " 1Z? !F,3!Q,#,R,V5X M,S$M,5]G96YU+FAT;5!+ 0(4 Q0 ( -"#PE;VS&VNK@< / G 7 M " ?ZF !F,3!Q,#,R,V5X,S$M,E]G96YU+FAT;5!+ 0(4 Q0 M ( -"#PE89.]=;/ 4 +\2 7 " >&N !F,3!Q,#,R M,V5X,S(M,5]G96YU+FAT;5!+ 0(4 Q0 ( -"#PE9H1W&"4@4 03 7 M " 5*T !F,3!Q,#,R,V5X,S(M,E]G96YU+FAT;5!+ 0(4 M Q0 ( -"#PE8VB^&UL4$L! A0#% @ T(/"5K_?PF,<9 *^,$ !4 M ( !-/@ &=F;V\M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0 ( M -"#PE:74B[B*B@ (UZ @ 5 " 8-< 0!G9F]O+3(P,C,P A,S,Q7W!R92YX;6Q02P4& H "@"B @ X(0! end